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ABSTRACT 
Systemic Sclerosis (SSe) is a progressive autoimmune disease characterized by 
vasculopathy, immune dysfunction and fibrosis of skin and internal organs. Pulmonary 
fibrosis is the most severe complication. Although pathogenesis of SSe is not completely 
understood, it is believed to be initiated by early and persistent damage to endothelial 
cells (ECs), which may initiate inflammation and activation of fibroblasts. In this study 
we used subcutaneous instillation of bleomycin (BLM), which induces skin and lung 
fibrosis similar to SSe. ECs are targeted by BLM, however, the extent of EC contribution 
to pulmonary inflammation and fibrosis , and the degree of vasculopathy in this model are 
not fully understood. The core hypothesis of this work is that BLM induced injury to 
ECs contributes to pathogenic processes, resulting in pulmonary fibrosis. Through a 
unique method of cell sorting and gene expression analysis, we demonstrated EC injury 
(Matrix Metalloproteinase 12, von Willebrand Factor) and activation in response to 
BLM. Activation of ECs was demonstrated by expression of selectins, chemokines, and 
cytokines, contributing to inflammation and macrophage recruitment. Direct contribution 
vii 
of ECs to fibrosis was demonstrated by up-regulation of pro-fibrotic cytokines 
(Osteopontin, Connective Tissue Growth Factor, Plasminogen Activation Inhibitor-!), 
activation of collagen production by fibroblasts , and expression of Endothelial to 
Mesenchymal Transition (EndoMT) markers (Fibronectin, Fibroblast Specific Protein- I). 
Importantly, responses were sustained, suggesting that ECs perpetuate damage and repair 
mechanisms that promote fibrosis. 
Previous work from our lab has shown that transcription factor Friend Leukemia 
Virus Integration-! (Flil) is down-regulated in fibroblasts and ECs in SSe, contributing 
to fibrosis and vasculopathy in the skin. Intriguingly, Flil is also down-regulated in the 
lung during BLM induced fibrosis, but not in ECs. Further studies demonstrated that Flil 
was down-regulated in macrophages, where it is regulated by inflammatory signals. Fli 1 
was also down-regulated in mesenchymal cells, which includes fibroblasts. Previous in 
vitro studies have shown that Flil regulates fibrosis through regulation of collagen and 
other extracellular matrix proteins. In this study, we identified Tissue Inhibitor of 
Metalloproteinase-3, an important molecule in collagen degradation, as a novel Flil 
target, revealing another mechanism by which Fli 1 contributes to development of 
fibrosis. 
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Fibrotic Diseases 
Summary 
INTRODUCTION 
Fibrosis 1s a pathological process in which excess collagen and extracellular 
matrix is deposited in tissue, destroying its normal architecture 1• Fibrosis can occur in 
many different organs including liver, lungs or skin. Systemic Sclerosis (SSe) is a 
connective tissue disorder in which fibrosis causes hardening of skin and internal organs 
2
. Interstitial Lung Disease (ILD) is one of the most common causes of mortality in 
patients with SSe, causing fibrosis of the lungs 3 . In addition to SSc-ILD, other forms of 
pulmonary fibrosis exist, including idiopathic pulmonary fibrosis (IPF) 4 . 
Systemic Sclerosis/Scleroderma 
Systemic Sclerosis/Scleroderma (SSe) is a progressive connective tissue disease 
characterized by vasculopathy, inflammation, autoimmunity and tissue fibrosis 3 . SSe 
afflicts women four times as often as men and onset is usually between the ages of 30 and 
50 years of age3 . Prevalence rates are as high as 240 cases per 1 million people in the 
United States, though estimates are lower in other countries 5. Fibrosis, the most 
characteristic feature of the disease, is defined by excessive and uncontrolled deposition 
of collagen and other matrix components. This causes hardening of the dermal layer of 
skin which may become swollen, tight and painful 2. A condition known as sclerodactyly 
is common in SSe patients, causing the fingers to curl and become immobile 3 . There are 
1 
two major forms of SSe, a diffuse form that afflicts large areas of skin and internal 
organs, and a limited form that mainly afflicts the limbs 2 . While limited SSe (lSSc) may 
typically be restricted to skin involvement, about 10% of these patients also suffer from 
pulmonary hypertension, which is associated with a poor prognosis 6. In diffuse SSe 
(dSSc) the kidney, esophagus, heart, lungs and other organs may be afflicted 2 . Renal 
crisis was once the most common cause of mortality; however treatment with ACE 
inhibitors has been effective 2. Currently the most severe complication in dSSc patients 
is pulmonary fibrosis 6. There is no cure for SSe, which is treated by maintenance of 
symptoms targeted at affected organ systems. This often involves anti-inflammatory and 
. . 2 ImmunosuppressiVe measures . 
While genetic factors may contribute to susceptibility of SSe, environmental 
factors are widely accepted to contribute to disease development. Environmental factors 
may contribute to tissue injury, but a single initiating source of injury is currently 
unidentified. Multiple environmental factors may contribute to pathogenesis in an 
individual 7. Consistent with this theory, reported concordance rates among monozygotic 
twins (MZ) are very low, roughly 5%, and equal to concordance rates among dizygotic 
(DZ) twins 8. The current paradigm exists that it is a combination of environmental 
triggers on a genetically susceptible host that is permissive for the development of SSe 7 . 
Genetic factors strongly suggest that inherited susceptibility is immunologically mediated 
9
. Genome wide association studies (GWAS) have shown an overwhelming number of 
immune-related genes with overlapping susceptibility factors to another autoimmune 
disease, systemic lupus erythematosus (SLE). Some of these alleles include IRF5, MIF, 
2 
STAT4, ITGAM and HLA-associations 9. Though concordance rates for SSe are low in 
MZ twins, there is a high concordance rate for the development of Antinuclear 
Autoantibodies (AN As) 8. In addition, development of multiple autoimmune diseases in 
an individual or within families has been frequently reported, suggesting that genetic 
factors predispose individuals toward autoimmunity rather than development of a 
particular disease 9. 
Autoantibodies are present in the serum of roughly 95% of SSe patients and have 
been classified into subtypes that correlate with different patient populations, disease 
severity and organ involvement 3. Some of the major subtypes that have been identified 
are 1) anti-centromere antibodies (CENP), which are correlated with lSSc and an 
increased risk for pulmonary arterial hypertension, 2) Anti-topoisomerase I antibodies 
which are associated with a poor prognosis and increased risk for ILD and 3) RNA 
Polymerase III antibodies which are associated with dSSc and renal disease, but 
associated with a better prognosis. Additional autoantibodies have been described, some 
which overlap with other autoimmune disorders, however the pathogenicity of 
autoantibodies in SSe are debated 10. It has been suggested that autoantibodies are one 
source of injury, initiating cellular damage and driving inflammation 3. 
Immune infiltrates have been identified in early SSe skin, with perivascular 
localization 3• 11 . The predominant immune cell types associated with SSe are T cells, 
monocytes/macrophages and occasionally, mast cells 3 . Research suggests that both T 
cells and macrophages play a pathogenic role in development of fibrosis. First, increased 
numbers of activated T cells are found within fibrotic lesions and in the blood of SSe 
3 
patients 3. T cell skewing is an active area of research and T cell subsets are associated 
with certain pathologies 1• Within fibrotic diseases, cells are predominantly Th2 skewed. 
These cells secrete elevated levels of IL4 and IL 13 cytokines, both of which have been 
shown to have profibrotic effects in vitro and in vivo 12. In addition, macrophages are a 
major source of cytokine production which further tissue damage and inflammation, as 
well as repair mechanisms 13 . Among the cytokines produced by macrophages, TGFP is 
the master regulator of fibrosis and directly activates fibroblasts to produce high amounts 
of extracellular matrix 14. 
Damage to the endothelium is believed to be one of the earliest events in SSe, 
leading to a progressive vasculopathy and driving fibrosis, characteristic of the disease 3 . 
Though no single trigger has been identified, immune involvement may be indicated in 
endothelial cell damage 15 . Viral infections, oxidative damage, toxins, and recently, 
endothelial cell autoantibodies, have all been suggested 15 - 17 . Evidence for injury 
includes the presence of von Willebrand factor (vWF) and endothelin-1 (ET-1) in the 
serum as well as circulating dead endothelial cells 2' 15 . The involvement of endothelial 
cell apoptosis has been debated 15 . It is possible that no single trigger is responsible, but 
a prolonged and persistent damage to the endothelium in the presence of improperly 
11 d . h . 18 19 contro e repau mec amsms ' . 
The earliest manifestation of SSe typically involves a vascular syndrome known 
as Raynaud's phenomenon, in which the digits change color in the presence of cold or 
other triggers 2 . This results from a vasospasm in which the control of vessel diameter is 
improperly controlled or overly sensitive 15 . This usually precedes the diagnosis of SSe 
4 
by many months and alone is not sufficient evidence for a diagnosis as it is seen in other 
connective tissue disorders and in roughly 10% of women as a primary syndrome 2 . 
Ensuing hypoxic conditions in SSe patients combined with tissue damage from ischemia-
reperfusion injury may result in digital ulcers, causing severe pain and immobility 20 . 
In addition to functional abnormalities in the maintenance of vascular tone, 
structural abnormalities are also characteristic of SSc-vasculopathy. Avascular areas are 
apparent in SSe patients due to capillary loss and insufficient angiogenesis and 
1 . 15 vascu ogenes1s . Contrary to this, circulating angiogenic mediators suggest a pro-
angiogenic environment, including high levels of Vascular Endothelial Growth Factor 
(VEGF), the most potent pro-angiogenic factor 19 . Angiogenesis is a complex process 
involving temporal and spatial control of vessel growth and remodeling of extracellular 
matrix, suggesting that the coordination of these processes is dysregulated in SSe patients 
20
. Vascular remodeling in SSe patients involves narrowing intima of large and small 
vessels, apparent as a systemic process in autopsy repmts 15 . Organ manifestations of 
proliferative vasculopathy are evident in the development of Pulmonary Arterial 
Hypertension (PAH) and Renal Crisis, which are exacerbated by functional abnormalities 
in vascular tone 3. Though Renal Crisis is effectively treated with Angiotensin 
Converting Enzyme (ACE) Inhibitors, PAH continues to contribute to a high mortality in 
SSe patients 2 . The combination of proliferative vasculopathy, structural changes of 
vessels, vasospasm and dysfunctional control of angiogenesis exacerbate SSe-
vasculopathy and organ dysfunction 3• 15• 20 . 
5 
Vasculopathy is an early symptom in SSe that progresses into later stages, 
overlapping with fibrosis. Pathogenesis of fibrosis is not completely understood, it is 
preceded by the development of inflammation and vasculopathy 3. Fibrosis is 
characterized by the activation of fibroblasts, resulting in excessive collagen production 
with reduced ECM turnover 21 . A number of different cell types (macrophages, 
endothelial cells, epithelial cells, etc.) and mediators (TGF~, CTGF/CCN2, IL4, IL13, 
etc.) may contribute to the proliferation and sustained activation of fibroblasts 22 . These 
concepts are reviewed in more detail later. 
Pulmonary Fibrosis and Interstitial Lung Diseases 
The lung is a vital organ that serves the critical role of providing oxygenated 
blood to the rest of the body and organ systems. Oxygen is delivered to the lungs by a 
complex series of airways that branch into smaller and smaller systems, until reaching the 
smallest unit, the alveoli. It is within these small air sacs that an extensive network of 
capillaries enables diffusion of carbon dioxide and re-oxygenation of blood. This entire 
process takes place across a very thin layer composed of epithelial cells, also known as 
type I pneumocytes, which are in close contact with the endothelium. Type II 
pneumocytes secrete pulmonary surfactant, a protein layer that reduces surface tension 
and enables transfer of gases. The interstitium is also composed of other cell types, 
including fibroblasts and alveolar macrophages 23 . Alveolar macrophages protect the 
lung from foreign material, dust and other particulate and maintain an anti-inflammatory 
environment under normal conditions by secretion of IL4, ILl 0 and TGF~ 24 . The lung 
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is susceptible to certain types of injury, including sustained injury or acute injuries of 
. d 23 great magmtu e . 
Interstitial Lung Diseases (ILD) is a heterogeneous category of disorders affecting 
the lung parenchyma. Though this classification encompasses many different diseases, in 
general ILD affects adults, with a slight prevalence of males over females (80.9/100,000 
males in the US as opposed to 67.21100,000 females) 25 . ILD has been separated into 
four groups by a universal classification system as of 2002 4. ILD is associated with 
Connective Tissue Disorders (Scleroderma, Systemic Lupus Erythematosus, and 
Rheumatoid Arthritis), or caused by a number of environmental factors such as 
occupational exposures (silica dust, asbestos), radiation, or certain dmg 
exposures/chemotherapeutic agents (Bleomycin) 4' 26' 27 . In the absence of a known 
etiology, ILD falls under the broad category of idiopathic interstitial pneumonias, which 
includes idiopathic pulmonary fibrosis (IPF) 4 . Symptoms of these disorders include 
difficulty breathing and shortness of breath (dyspnea), dry cough, and aggravation of 
symptoms upon exertion 26 . Breathing difficulties stem from the extensive extracellular 
matrix deposition within the functional compartment of the lung that allows air exchange, 
the alveoli 23• 28 . With extensive involvement, the lungs become hardened and are 
difficult to expand, thus dyspnea ensues. Treatment often involves immunosuppressive 
therapy, similar to SSe, as well as removal from the identified causative agent, if known, 
and in some cases, supplemental oxygen or lung transplantation 4' 27 . Prognosis is 
generally poor for ILD but depends on the form of the disease, outlook is worst for IPF 
patients with a median survival of 2-3 years 4 . Though prognosis of SSe patients with 
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ILD (SSc-ILD) is better than IPF patients, prognosis is still poor and continues to be the 
major cause of mortality in SSe 6 . 
The general progression of fibrosis is similar in different tissues and involves 
injury, inflammation and ECM deposition 29 . Injury to the tissue results in an 
inflammatory process and complex interactions between multiple cell types seem to drive 
the activation of fibroblasts, resulting in tissue fibrosis 22 . In the lung and other organs, 
macrophages are considered to be one of the central cell types in the fibrotic process. 
Macrophages secrete a wide array of mediators that have multiple effects 13• 30. First, 
cytokines and chemokines amplify the inflammatory reaction by recruiting other immune 
cells, including macrophages and neutrophils 11 . Secondly, secretion of ROS, RNS and 
proteases causes direct damage to tissues, which has its own effects on fibroblast 
activation 30 . Within the lung, damage to Type I pneumocytes (either from the initial 
injury or from the macrophage response) induces the proliferation of Type II 
pneumocytes 31 . These complex cellular interactions contribute to a profibrotic 
environment in which mediators secreted from many different cell types including 
macrophages, neutrophils, epithelial cells, endothelial cells and fibroblasts themselves, all 
have the ability to induce fibroblast proliferation, recruitment and activation 23 . More 
details of these interactions are reviewed in Figure 1. 
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Figure 1: Mechanisms of Pulmonary Fibrosis. Fibrosis is a pathological condition that 
is often described as an over-activation of normal wound healing responses. Fibroblast 
activation is the central process of fibrotic diseases, leading to the production of collagen 
and other extracellular matrix proteins that are deposited within the tissue. Though TGFf3 
and other pro-fibrotic cytokines are responsible for the activation of fibroblasts, multiple 
cell types are involved in the process that leads to activation of fibroblasts. First, damage 
to epithelial cells or endothelial cells activates innate immune responses including 
recruitment of neutrophils and monocytes. These cell types secrete mediators that cause 
further tissue damage and may directly activate fibroblasts to produce collagen. More 
recently, T cells have also been implicated in modulating the fibrotic response through 
the action ofiL-4 and IL-13, which are Th2 cytokines associated with fibrosis. (Original 
Publication: Wynn 1) 
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Bleomycin Model of Pulmonary Fibrosis 
Bleomycin (BLM) is an antibiotic that is used to treat certain cancers of the head, 
neck and reproductive tracts due to its anti-tumor activity 32 . It is a mixture of 
glycopeptides isolated from the bacterium Streptomyces verticil/is and sold under the 
brand name Blenoxane by Bristol Myers Squibb 33 . Its use is limited by severe side 
effects including chest pain and shortness of breath (dyspnea). Pulmonary toxicity is a 
well-known side effect of Bleomycin, most commonly beginning as pneumonitis that 
may progress to pulmonary fibrosis in a subset of patients. Upon discovery of pulmonary 
fibrosis as a side-effect, BLM became the most commonly used model of IPF and SSe 
fibrosis of the lung and skin 34 . Bleomycin toxicity in humans has led to use of the drug 
as an animal model of both pulmonary and dermal fibrosis 35 . Its experimental use has 
been described as early as the 1970s in rodents such as hamsters, rats, or most commonly, 
mice. The most popular method involves a single intratracheal (IT) dosage, a single 
intravenous (IV) injection or multiple intraperitoneal (IP) or subcutaneous injections 
(SubQ) 36' 37 . All methods of instillation have been shown to induce pulmonary 
inflammation and fibrosis, but only the subcutaneous route induces dermal fibrosis 
through daily injections36 . All modes of drug delivery have been shown to induce 
damage to endothelial and epithelial cells in the lung 32, causing an inflammatory 
response predominantly characterized by macrophage and Th2 cell infiltration and 
resulting in fibrosis 35 . While all methods present similar histopathology, serum cytokine 
profile, and pathogenic mechanisms of fibrosis, a few key differences have been noted34. 
One publication comparing different BLM models of pulmonary fibrosis noted an early 
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inflammatory response in IT instillation, with more T cell and neutrophil infiltration than 
SubQ injection, while there was a more predominant macrophage infiltration during 
SubQ injection 38 . It is important to note that the inflammatory response from the IT 
route produces a biphasic response, with an early inflammatory reaction that appears to 
be partly mediated by a non-specific reaction to fluid instillation directly into the lung, 
causing direct damage to epithelial cells 34. It is well known that different mouse strains 
have variable susceptibility to ELM-challenge with C57Bl/6 mice being fibrosis-prone 
and Balb/c mice are resistant, but can develop fibrotic lesions with high dosage 35 . 
Studies have shown that BLM susceptibility depends on dosage, length of exposure, 
genetic background, ability to repair DNA damage, ability to degrade the drug, immune 
response and Thl/Th2 bias 35 ' 39 . Similar to human ILD, fibrotic areas in animals treated 
with SubQ and IV BLM develop subpleural and perivascular lesions, where fibrotic 
areas in IT instillation are localized predominantly to peribronchial and peribronchiolar 
areas 
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Bleomycin was shown to cause damage to both endothelial and epithelial cells in 
vivo 32• 41 . Adamson and Bowden used electron microscopy to describe endothelial 
blebbing and separation from the basement membrane as a primary site of injury 
following injection of the drug 41 . They also described necrosis of type 1 alveolar 
epithelial cells followed by proliferation of type 2 epithelial cells 42 . In vitro studies have 
also described cell damage and apoptosis as a result of direct BLM stimulation. Cells 
treated with BLM show a dosage dependent DNA fragmentation, caspase activation and 
mitochondrial dysfunction 43 . Studies on epithelial cells have revealed the presence of 
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apoptosis through multiple mechanisms, while work on pulmonary aortic endothelial 
cells have shown that caspase 8-dependent pathway precedes the intrinsic (mitochondrial) 
apoptotic pathway 32' 43 . 
Extensive in vitro studies have characterized the cell-specific responses to 
bleomycin and mechanism of cell damage. Bleomycin forms an activated complex by 
the chelation of iron or copper 33 . This takes place either within the blood when 
administered by intravascular methods, or within the cell. It is believed to enter the cell 
by recognition of a cell surface receptor and subsequently taken up through endocytosis 
33, 44 Once in the cell the activated complex reacts with oxygen to oxidize lipids, 
hydrolyze amide bonds of proteins and cause strand breaks in both DNA and RNA 33, 43 . 
The cell response to damage is dependent upon the cell type and drug dosage and may 
result in either DNA repair, cell cycle arrest, apoptosis or activation of the cell 33 . 
In vitro work in fibroblasts and macrophages has shown that bleomycin induces 
cell-specific responses, causing activation of both cell types. Stimulation of fibroblasts 
with bleomycin has shown effects on the DNA damage response, cell cycle arrest and 
enrichment of apoptosis genes by microarray 45 . The effects on G2/M cell cycle arrest 
and apoptosis is dosage dependent. Further analyses have shown that direct stimulation 
of fibroblasts may induce production of collagen 45 ' 46 . Alveolar macrophages are also 
activated in response to bleomycin treatment in vitro, inducing production and secretion 
of chemotactic factors for macrophages and growth factors that induce proliferation of 
fibroblasts 47 . Stimulation of macrophages may be dependent upon recognition of the 
drug by TLR2 or TLR4 48 . Additional in vivo evidence has suggested a second, indirect 
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mechanism of macrophage activation through a cell damage response. The indirect 
mechanism is a more general cell damage response, causing recognition of endogenous 
ligands by damage associated molecular patterns (DAMPs) 11 . 
Cellular Mechanisms of Fibrosis 
Summary 
Activation of the fibrotic process involves cross-talk of many different cell types. 
In SSe, vasculopathy and inflammation precedes the development of fibrosis and 
contributes to tissue damage 3. This leads to the eventual recruitment, proliferation and 
activation of fibroblasts 49 . Many cell types secrete mediators that activate fibroblasts to 
myofibroblasts, including macrophages, T cells, endothelial cells, epithelial cells and 
fibroblasts themselves 22 . While activation of resident fibroblasts is one potential source 
of myofibroblasts, other cell types are implicated as precursors; including monocyte 
precursors (fibrocytes), pericytes, smooth muscle cells, epithelial cells, and endothelial 
cells 50 . Conversion of epithelial cells to fibroblasts is a well-documented process known 
as epithelial to mesenchymal transition (EMT) 51 . A more recently defined and emerging 
field has focused on the process of endothelial to mesenchymal transition (EndoMT), 
which closely resembles EMT 52' 53 . 
Inflammation/Innate Immunity 
Among the inflammatory cells in fibrotic tissues from human and animal tissues, 
macrophages are a predominant cell type and are believed to influence the proliferation, 
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recruitment and activation of fibroblasts 11 . They are found in small numbers in most 
tissues under normal conditions, and are differentiated from monocytes upon recruitment 
into tissue. Originally thought to be merely scavenger cells, they phagocytose up to 
2x 10 11 erythrocytes per day in addition to cell debris and apoptotic cells 54 . It is now 
known that macrophages are highly plastic cells that have diverse functions, mediating 
both innate and adaptive immunity, and contributing to wound healing responses 54 . 
Maintenance of homeostatic conditions is an important function of macrophages, they 
phagocytose apoptotic and cellular debris in the absence of danger signals. Danger 
signal come through activation of pattern recognition receptors (PRRs) such as Toll-like 
receptors (TLRs), C-type lectin receptors, mannose receptors, NOD-like receptors 
(NLRs) and RIG-I-like receptors (RLRs) 55 . These receptors recognize conserved 
molecular patterns on microbes, termed pathogen associated molecular patterns 
(PAMPs), or they recognize endogenous ligands, termed damage associated molecular 
patterns (DAMPs). Upon PRR activation by engulfed pathogens, or in response to tissue 
damage, macrophages launch an immune response 55 . Macrophages have been shown to 
secrete over 100 mediators which may include cytokines, ROS, RNS, lipid mediators or 
hydrolytic enzymes which have effects on an array of different cells types, including 
non-hematopoietic cells 30 . The adaptive immune response is controlled by secreted 
d o d hr h • f • 54 56 me 1ators an t oug presentahon o antigens · . 
Macrophages are highly plastic cells with diverse functions depending on 
h 0 0 ° 13 responses to t err m1croenvuonment . Activation signals were first described in 
response to a combination of IFNy and cytokines, or in response to LPS alone. These 
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signals led to enhanced microbicidal activity, including enhanced ROS/RNS production 
and secretion of pro-inflammatory cytokines (IL 1, TNF a, IL-6) 57 . They expressed high 
IL12 and IL23 and low amounts of the anti-inflammatory cytokine IL-10 56 . It has since 
been described that macrophages are activated by an array of different signals, many of 
which do not result in enhanced microbial killing54. One paradigm mimics the 
nomenclature ofT helper cells that differentiate into Thl or Th2 subtypes, renaming the 
pro-inflammatory/enhanced killing phenotype of macrophages as Ml, or, "Classically 
activated macrophages (CAM)" and other types of macrophage activation have been 
grouped into M2, or, "Alternatively activated macrophages (AAM)" 58 . The term, 
altemative activation, has since caused confusion for a couple of reasons. First, the term 
"activation" suggests an enhanced immune response, while the M2 phenotype is often 
associated with anti-inflammatory properties 54' 56 . Second, it is widely accepted that the 
M2 phenotype has become a generic name that describes many different functions of this 
cell type 54• 56 . The current understanding of macrophage activation is continuing to 
evolve and adapt to account for macrophage heterogeneity and plasticity of this cell type. 
Alternative activation of macrophages was first described following IL4 
stimulation; this resulted in high production of the anti-inflammatory cytokine, ILlO, and 
low production of IL12 and IL23, characteristics of CAM 57 . The production of 
inflammatory cytokines is variable with high expression of the following markers: MHC 
II, CD206, FIZZl/Relma, Chitinase activity (YMl, YM2) and Arginase activity (Argl, 
Arg2) 56 . While T helper cells undergo epigenetic modification during the differentiation 
process, macrophage skewing appears to be reversible. Macrophages continue to respond 
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to environmental factors and may display hybrid phenotypes 54 . There have been various 
suggestions made to change the current paradigm, accounting for the diversity of 
functions currently characterized as "alternative activation". Mosser and Edwards 
proposed a model of macrophage activation, likening it to a color wheel. Three main 
functions of macrophages; host defense, wound healing and immune regulation, each 
represent a primary color in the circle. Similar to the blending of colors, macrophages 
may display a spectrum of phenotypes that encompass at least three m~jor functions 54 . 
Other reports have suggested that macrophages be described as "M2" and "M2-like" or 
proposed further definitions of M2 macrophages as M2a, M2b, M2c, etc. 57 
There are different types of macrophages within the lung which includes alveolar 
macrophages and interstitial macrophages, differentiated by their location and cell 
surface marker expression24, such as CDllb and CD11c59 . Alveolar macrophages reside 
within the alveolar spaces and clear foreign particulate and pathogens that are inhaled 24 . 
They have been associated with both pro and anti-inflammatory properties, but must 
maintain a relatively inactive state under most conditions. With constant exposure to the 
outside environment, it is postulated that they "silently" clear debris and avoid activation 
under most conditions 24. Interstitial macrophages reside within the matrix between the 
alveolar epithelium and the endothelium of capillaries, a relatively sterile environment in 
close contact with many other cell types 24 . Alveolar macrophages are easy to purify 
from the bronchiolar lavage (BAL) fluid and much more is known about this cell type as 
opposed to interstitial macrophages 24 . 
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Macrophages are believed to be primary mediators of lung injury, often resulting 
in fibrosis 58. Consistent with this is the fact that macrophages infiltrate the lung upon 
injury 30, are found in close proximity with collagen producing fibroblasts, and are known 
to be one of the major producers of TGFP 58 . Upon activation, macrophages secrete 
cytokines and other mediators as part of the inflammatory process. This contributes to 
cytotoxicity and allows further recruitment and activation of macrophages 30 This 
becomes a circular process in which macrophages are activated in response to lung injury 
and amplify the response. Acute lung injury may be self-limited or progress to fibrosis if 
severe or persistent, swaying the environment towards one that favors fibrosis 58 . 
In addition to ELM-induced tissue injury, activation may also be the result of 
direct stimulation of macrophages with BLM. In vitro studies have shown that BLM is 
able to bind to macrophages 60 and activates the secretion of cytokines 61, some of which 
contribute to fibroblast activation 62 . It was later proposed that BLM is recognized by 
both TLR2 and TLR4 63, partially accounting for the pro-inflammatory effects of BLM 
treatment on macrophages in culture. Thus, macrophage activation during fibrosis can 
either be a result of direct PRR stimulation from P AMPS, or an indirect stimulation due 
to tissue injury and recognition of DAMPS, such as hyaluronan and ECM fragments 48' 64. 
Though the presence of M2 macrophages is well accepted during fibrotic 
diseases, little is known about the function of commonly accepted markers for this cell 
type 1• For example, the chitinases are a family of enzymes that degrade polymers of 
insect and crustacean exoskeletons and fungal cell walls, consistent with their association 
in protection against extracellular pathogens 13 . Though chitinases are known to be up-
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regulated during ELM induced lung injury and fibrosis, idiopathic pulmonary fibrosis 
and sarcoidosis, and are associated with the alternative activation phenotype of 
macrophages, their role in mediating fibrotic responses is not conclusive 58. Similar 
associations to fibrosis have been noted in the Relm family of molecules, but conditional 
deletion is necessary to determine their role in macrophage function 58 . Arginase 1 has 
been suggested as a regulator of the wound healing phenotype, but conditional deletion in 
macrophages exacerbated a mouse model of fibrotic liver disease. Thus, though M2 
macrophages are associated with fibrotic disease, additional studies will need to further 
determine the precise function of M2 markers during fibrosis 58 . The Th2 cytokines, 
IL4/IL13, are implicated in fibrosis and drive M2 differentiation of macrophages, 
suggesting that M2 macrophages are also associated with fibrotic processes 1. Yang, et al 
characterized the response of macrophages to ELM-induced pulmonary fibrosis. Ml 
macrophages (CDllb+ F4/80+ CD206-) predominated early after ELM-injury and 
correlated with the pro-inflammatory phase. Later in the response, M2/altematively 
activated macrophages took over and were correlated with the fibrotic phase of ELM-
induced lung injury 48 . 
Fibroblast Activation and Wound Healing 
Fibroblasts are mesenchymal cells that are responsible for the production of 
collagen and other matrix proteins that make up the structure of connective tissue 65 . 
Though they secrete very little collagen under normal conditions, they respond to 
environmental cues upon injury and act to repair damaged tissue 22 . Upon activation, 
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fibroblasts may respond by migrating towards damage and secrete extracellular matrix 
that is necessary for repair 21 . Fibroblasts are also implicated as the main source of 
dysregulated collagen production during the pathological process of fibrosis 22. 
Wound healing is a complicated process that involves many different cell types 
and signals from the external microenvironment. Immediately following injury, 
granulation tissue, composed of fibronectin, vitronectin and collagens II, N, V and VI 
are laid down 66 . This provisional matrix is later remodeled with more permanent 
connective tissue composed of collagen I 67 . TGF~ is considered the master regulator of 
both wound healing and fibrosis and is produced by macrophages, platelets and 
fibroblasts upon injury 22 . It is has many effects on fibroblasts including proliferation, 
migration, synthesis of extracellular matrix and induces differentiation of myofibroblasts 
68
. Myofibroblasts are an activated state of a fibroblast that form during wound healing. 
They actively synthesize collagen, with the additional ability to exert force, or 
contraction, on the extracellular matrix through the expression of stress fibers 22 ' 69 . 
Differentiation of myofibroblasts requires two steps; including a change in the 
mechanical stress of surrounding connective tissue, and responses to growth factors, 
including TGF~ 49 . Upon activation, they express a-smooth muscle actin (aSMA), 
considered to be the most reliable marker for myofibroblasts. Expression is essential for 
contractility in wound closure 68 . The wound healing process ends with epithelialization; 
the proliferation and movement of epithelial cells over the wound. Under normal 
conditions the wound healing process leaves minimal scar formation and myofibroblasts 
undergo apoptosis following epithelialization. However, fibrosis is characterized by 
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persistence of myofibroblasts that are resistant to apoptosis and continue to deposit 
collagen for years 49 . 
During fibrosis, it is hypothesized that activated fibroblasts persist within the 
tissue and are resistant to normal death signals 22 . In SSe, abnormalities in signaling 
pathways including apoptosis have been extensively reported. Resistance to Pas-
mediated apoptosis in SSe dermal biopsies was reported by two groups, this was 
attributed to a change in the ratio of proteins that regulate apoptotic signals, Bcl-2 and 
Bax 70' 71 . In a publication by Jelaska and Korn, TGF~ treatment had an anti-apoptotic 
effect on normal fibroblasts, suggesting that dysregulation of the TGF~ pathway may be 
partially responsible for resistance of apoptosis in SSe fibroblasts 71 . Reduced expression 
of acid sphingomyelinase (ASMase), which is regulated by TGF~, represents one 
mechanism by which SSe fibroblasts are resistant to Fas mediated apoptosis 72 . 
In vitro studies support the notion that fibroblasts from SSe patients exhibit 
abnormalities in TGF~ signaling, including excess collagen production 73 and hyper-
responsiveness to external signals 74' 75 . In a study comparing normal and SSe fibroblasts, 
it was determined that fibroblasts secrete more collagen in response to supplemental 
serum, suggesting that factors within the serum induced pro-fibrotic changes 73 . 
Importantly, fibroblasts from SSe biopsies exhibited greater increases in collagen 
production than normal fibroblasts 74. While over-production of TGF~ protein has been 
noted in SSe biopsies 76-78, SSe fibroblasts display irregular responses to growth factors. 
This suggests that changes within the fibroblasts themselves are partially responsible for 
the SSe phenotype. 
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Sources of Myofibroblasts 
Activation of fibroblasts into myofibroblasts during fibrosis mimics the normal 
process of wound healing. While fibroblasts/myofibroblasts are considered to be the 
main producers of collagen and are known to be present in fibrotic tissue, the source of 
fibroblasts/myofibroblasts during tissue fibrosis has been a subject of debate 50 . Recent 
evidence has shown that, in addition to resident fibroblasts, other cell types have the 
potential to differentiate into myofibroblasts during fibrosis and wound healing. 
Proposed cellular sources of fibroblasts include local proliferation of stromal cells 
(fibroblasts, smooth muscle cells and pericytes)50, transformation of epithelial cells or 
endothelial cells, or recruitment of cells from the bone marrow (termed "fibrocytes") 69 . 
Epithelial to mesenchymal transition (EMT) has been studied extensively in the 
context of embryonic development and is believed to be a contributing mechanism to 
pulmonary fibrosis 79 • The emergence of fate tracing has revealed other cell types as the 
primary sources of myofibroblasts and suggested that EMT is more prevalent in vitro 
than in vivo. An emerging concept in fibrosis research has used fate tracing to reveal the 
prevalence of perivascular cells as the predominant origin of myofibroblasts in kidney 
fibrosis, muscle injury and wound healing models 80• 81. 
Epithelial Cells 
Epithelial cells are found throughout the body, cover the skin and internal organs, 
offer protection and have various functions in different organs. Depending on the 
location of epithelial cells, they may function as secretory cells, protective barriers, form 
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permeable layers and assist in transport. Within the lung there are two types of epithelial 
cells, Type I alveolar epithelial cells (AECs) are in close proximity with the capillaries 
and cover roughly 95% of the surface area of alveoli and are very sensitive to injury 23 ' 31 . 
Type II AECs are more resistant to injury and have a specialized function in the secretion 
of surfactant 31 . Type II AECs also function as progenitors for type I AECs and are found 
at the comers of alveoli, in close proximity to mesenchymal cells, allowing 
communication of these cell types 82 . During injury type I AECs undergo apoptosis and 
the process of re-epithelialization involves the proliferation of Type II cells, a process 
that influences the behavior of nearby fibroblasts 23 ' 51 (Figure 1 ). 
A current working hypothesis for IPF is that the wound healing process goes awry 
due to multiple cycles of epithelial injury and activation 51 . Epithelial injury can 
influence the behavior of fibroblasts by a couple of mechanisms. First, the re-
epithelialization process involves secretion of mediators such as TGF~ and ET -1, 
influencing activation, proliferation and recruitment of nearby fibroblasts 51 . Consistent 
with this view, epithelial injury precedes the development of fibrosis in the BLM model 
of pulmonary fibrosis. Secondly, TGF~ has been shown to drive a process known as 
epithelial to mesenchymal transition (EMT), in which type II pneumocytes lose their 
properties as epithelial cells and become fibroblast-like 31 ' 83 ' 84. 
EMT is an active area of research that has been extensively studied through in 
vitro techniques and through in vivo models of lung and the kidney fibrosis. In lung 
disease, EMT has been implicated in both human ILD 31 and in mouse models of 
pulmonary fibrosis 51 . In an influential study by Kim, et al, an intranasal TGF~ model 
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was used to show EMT in what they described as the "strongest evidence to date" for the 
involvement of EMT in pulmonary fibrosis 83 . The extent to which EMT contributes to 
the total accumulation of ECM in kidney and lung fibrosis is yet to be determined. 
Furthermore, we need to determine whether the role of EMT in fibrosis is universal and 
can be applied to fibrosis in other organs, such as in SSe dermal fibrosis. 
Epithelial to mesenchymal transition (EMT), and a related process known as 
Endothelial to mesenchymal transition (EndoMT, which will be described in more detail 
later) are very similar processes. The transition process is gradual and is mediated by 
TGF~, the main fibrotic cytokine 69 • Over time, cells lose their cell-cell attachment 
properties and become more mesenchymal-like. During this process, cells gain 
mesenchymal markers (aSMA, vimentin, FSPl), express EMT/EndoMT transcription 
factors (Snail, Slug, Twist, ~-catenin) and lose their cell specific markers (E-cadherin for 
epithelial cells; CD31 and VE-cadherin for endothelial cells) 51 ' 84. In vitro data supports 
these claims, as cultured epithelial or endothelial cells treated with TGF~ co-express their 
cell specific markers and the prototypic myofibroblast marker, aSMA 31 . The presence 
and extent ofEMT or EndoMT in vivo is debated and has been shown to variable degrees 
in different organs. In vivo, the current gold standard measure is through cell lineage 
tracing studies in transgenic animals. As cells in transition, they may lose their original 
cell markers. It is essential that they are labeled irreversibly by GFP, ~-gal or another 
suitable marker 84 . 
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Endothelial Cells 
Endothelial cells are specialized cells that line both large and small blood vessels 
throughout the body and have an important role in the coagulation cascade, 
inflammation, maintenance of blood pressure and angiogenesis 85 . They maintain a 
barrier between the bloodstream and tissue and control the passage of materials through 
the endothelium. Upon breach of this barrier, the endothelium is important in the 
control of thrombosis and fibrinolysis , and therefore, in the formation of blood clots 86 . 
In scleroderma, endothelial damage and dysfunction leads to improper control of 
vasoconstriction and vasodilation 15. In addition to SSc-vasculopathy, the endothelium 
may contribute to the development of fibrosis through the control of inflammation and 
leukocyte homing or through more direct interactions with fibroblasts. 
The process of leukocyte extravasation is complex, involving interactions 
between immune cells from the blood and signals within the tissue and endothelium 87 . 
Leukocytes are constantly in circulation but do not migrate into tissue until they receive 
the proper signals, including interactions with adhesion molecules along the endothelium 
and a gradient of chemoattractants 88 . Chemoattractants are released along the 
endothelium and home leukocytes to the vascular wall and towards sites of vascular or 
tissue injury. Though chemokine responses are considered redundant and promiscuous, 
many chemokines of the CC family attract monocytes and the CXC family recruits 
mainly neutrophils 89 . Leukocytes are attracted towards higher gradients of chemokines 
and begin to slowly roll along the endothelium when coming in contact with adhesion 
molecules. Expression of the selectin family (E-selectin, P-selectin) of adhesion 
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molecules is induced very early along the endothelium during the inflammatory response, 
forming interactions with ligands expressed along the leukocytes. These interactions are 
responsible for loose, slow rolling interactions of leukocytes along the vascular wall 90. 
They adhere more firmly as stronger interactions within the integrin family take over, 
causing the leukocyte to roll slowly and allowing it to be pulled through the endothelium. 
Once pulled through the endothelium, leukocytes migrate through the tissue towards sites 
of injury, attracted once again toward a chemokine gradient 23 ' 91 . Once within the tissue, 
immune cells may contribute to the release of cytokines and pro-fibrotic mediators, 
leading to activation of fibroblasts. 
Endothelial damage and activation is often measured by serum markers in the 
blood. Increased levels of von Willebrand Factor (vWF) and angiotensin converting 
enzyme (ACE) in serum are suggestive of endothelial damage in SSe patients 92• 93, 
potentially contributing to inflammation. Evidence of endothelial activation in SSe 
comes from the presence of soluble adhesion molecules and chemokines (predominantly 
from the CCL family) in the blood, including: sVCAM-1, sE-Selectin, CCL2, CCL3, 
CCL4 and CXCL8 94-96 . Furthermore, CCL2 and CCL3 have been correlated with 
pulmonary fibrosis and CCL2 expression has been confirmed in the endothelium of skin 
biopsies from SSe patients 97. Though blood and BAL are relatively easy fluids to obtain 
from humans, it is often difficult to localize the cell type contributing to secretion of these 
mediators as immune cells and endothelium may be contributors. The use of animal 
models of fibrotic diseases complements what is known from clinical data and may assist 
in identifying cell specific responses. 
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In addition to contributing to inflammation, endothelial cells may influence 
fibrosis through more direct mechanisms, affecting the growth, proliferation and 
activation of fibroblasts. Yin, et al showed that endothelial cells isolated from ELM-
stimulated rats induced activation of fibroblasts through a co-culture system. The 
transformation to myofibroblasts, shown by expression of aSMA and secretion of 
collagen, was attributable to secretion of pro-fibrotic mediators CTGF and TGF~ 98 
These data are consistent with the fact that activated endothelial cells have been shown to 
secrete cytokines and pro-fibrotic mediators. Upon direct activation of endothelial cells 
with BLM in vitro, endothelial cells increase expression and secretion of TGF~, CTGF 
and PAI-l 99- 101 . Other recent studies have suggested that EndoMT may be activated 
during BLM induced fibrosis and SSe, creating fibroblast-like cells from the endothelium 
which contributes to ECM synthesis 52 . 
Endothelial to mesenchymal transition has been best described during embryonic 
heart development and has been implicated during heart fibrosis 53• 84. The existence of 
EndoMT as a fibrotic process in other organs is an active area of research that was 
recently reported in the BLM model of pulmonary fibrosis 52' 102. Another study 
suggested that local proliferation of stromal cells contributed to fibrotic foci within the 
lung, while excluding epithelial cells as a source of fibroblasts in the BLM model. This 
study, however, did not include the possibility of endothelial contributions to fibroblasts 
during fibrosis 50 . While it is clear that there is much debate as to the cellular sources of 
fibroblasts during organ fibrosis, it is possible that the development of fibrosis may be 
multifactorial. The contribution of individual cell types may first depend on the organ 
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type and composition of tissue in that particular organ and second may depend on the 
type of injury and target cell. Consistent with this theory, one report used cell lineage 
tracing in two different models of dermal fibrosis. During dermal excision and wound 
repair, bone marrow derived fibrocytes were not present within the tissue in contrast to 
the limited numbers of fibrocytes found within the skin after BLM induced dermal 
fibrosis, as part of the same study 103 . Though the end result of injury is fibrosis, there 
are many cell types that may have the potential to differentiate into fibroblast-like cells 
and secrete ECM. 
Mediators of Fibrosis 
Summary 
Pro-fibrotic mediators are secreted from inflammatory cells, epithelial cells, 
endothelial cells and fibroblasts during wound healing and fibrosis 22 . TGFP is 
considered to be the "master regulator of fibrosis" by influencing the proliferation and 
migration of fibroblasts, differentiation to myofibroblasts, and secretion of collagen and 
other ECM proteins 104. CTGF is a target of TGFP and is involved in a pro-fibrotic loop 
as it also works synergistically with TGFP in the production of collagen 105 . Many of the 
effects of TGFP are carried out by signaling events mediated by Smads, which also 
function as transcription factors 104. In addition to Smads, TGF~ regulates the expression 
of the Ets family of transcription factors, including Fli 1, which is an important inhibitor 
of collagen synthesis that is down-regulated in SSe 106. The Th2 cytokines family (IL-4, 
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IL-13) has also been implicated in fibrosis , through direct activation of collagen synthesis 
in fibroblasts and activation ofM2 differentiation I, 58. 
Transforming Growth Factor p (TGFfJ) 
TGFP is an anti-inflammatory cytokine with an important role in the regulation of 
extracellular matrix. It is known to induce expression of ECM mRNA and protein, 
including the production of collagen, fibronectin and glycoasminoglycans in fibroblasts. 
Inhibition of ECM degradation has also been noted through downregulation of matrix 
metalloproteinases (MMPs) and upregulation of tissue inhibitors of MMPs (TIMPS). 
Activated fibroblasts adhere strongly to the extracellular matrix and are also noted to 
secrete TGFP themselves, potentially forming an autocrine loop 14. TGFP induces 
activation, proliferation and migration of fibroblasts 68, an effect that has been shown 
through wound healing studies on TGFP deficient mice. A TGFP 1 knockout mouse was 
viable but had a severe phenotype; including immune cell infiltration in organs 
(consistent with its anti-inflammatory properties), wasting syndrome, bone deformities, 
and increased epidermal growth 107 . In addition to defects in epithelial and immune cells, 
TGFPl knockout mice exhibited impaired wound healing 107, and in rats, wounds treated 
locally with TGFP 108 exhibited accelerated wound healing with increased collagen 
deposition. Further supporting the claim that TGFP regulates production of ECM in vivo, 
TGFP2 was co-localized to proal (I) collagen in dermal biopsies from SSe patients 77 . 
Using a combination of gene expression analysis and histological measures, there is 
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extensive data to implicate TGFP dysregulation during dermal and pulmonary fibrosis in 
humans. 
Increased expression of the TGFP isoforms has been reported in endothelial cells, 
immune cells and the extracellular matrix of SSe dermal and lung biopsies using either in 
situ hybridization or immunohistochemistry, when compared to healthy control biopsies 
77
• 
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. Though multiple reports have challenged these conclusions, it has been 
proposed that the expression of TGFP in the skin is dependent upon the stage of the 
disease 14. Querfeld, et al showed that all three isoforms of TGFP were up-regulated in 
dermal biopsies of patients with dSSc and lSSc with inflammation but not in patients 
biopsies with sclerotic skin, supporting the claim that expression is dependent on the 
stage of disease 78 . Further evidence suggests that dermal biopsies from SSe express 
elevated levels of TGFPRI and TGFpRII, possibly contributing to the proposed hyper-
responsiveness of SSe fibroblasts to TGFP 111 . Using a molecular approach, the 
Whitfield lab has identified a subset of patients that express a TGFP "gene signature" by 
comparing the gene profile of healthy fibroblasts treated with TGFP to the gene profiles 
from patient biopsies. A subset of biopsies seemed to resemble that of a healthy 
fibroblast treated with TGFp, and was labeled as having a "TGFP signature", while no 
healthy biopsies were identified under the TGFP gene signature 112• 113 . 
TGF0 is a cytokine important for many cell processes including growth, 
proliferation, embryonic development and apoptosis. Its actions are cell and context 
specific and depend on signals from many converging pathways. Within the TGFP 
superfamily, ligands include the prototypic Transforming Growth Factor p (TGFp), Bone 
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Morphogenic Proteins (BMPs), Growth Differentiation Factors (GDFs) and Activin 
families. During signaling, a homodimerized ligand binds to a constitutively active Type 
II receptor with Serine/Threonine kinase activity. This event causes formation of a 
complex with Type I and Type II Receptors, composed of at least two molecules of Type 
I and type II receptors, and often contains co-receptors endoglin or betaglycan. After 
ligand binding, Type I receptors are phosphorylated and activated by Type II receptors, 
changing their conformation and allowing binding of members of the Smad family, 
which carry out internal signaling. Within the Smad family there are receptor regulated 
Smads (R-Smads), Inhibitory Smads (I-Smads) and one identified Co-Smad (Smad4). 
When an R-Smad binds to an activated Type I receptor, it becomes phosphorylated and 
activated. Phosphorylated R-Smads then dimerize with Smad4, which is required for 
dimerization and signaling of all Smads. This results in nuclear translocation of the Smad 
complex, which acts as a transcription factor. Within the nucleus the Smad complex 
recognizes Smad Responsive Elements (SRE) and controls transcription of target genes 
68, 114 
Signaling through TGFPl is often called "canonical signaling" and was the first 
ligand to be described. The TGFP 1 ligand binds to TGFPRII and Alk5, a member of the 
TGFPRI family. Signals are transmitted to the nucleus through oligomers of Smad 2 and 
3 complexes with Smad4. Within BMP signaling, ligands transmit their signals through 
complexes ofBMPRII with the Type I receptors (Alk3 or 6) and signal through Smads 1, 
5 and 8 (Figure 2). Considerable cross-talk exists within these pathways. For example, 
TGFP signaling through Smads 1, 5 and 8, which are typically described as part of the 
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BMP pathway, have now been described in both physiological 11 5 and pathological 
conditions 116• 117, signaling through the Alk 1 receptor. 
Dysregulation of TGF~ signaling has been implicated in SSe by the observation 
that SSe fibroblasts over-express ECM, a phenotype that is inhibited by antibody 
blockade of TGFP 11 8. While SSe fibroblasts do not secrete an abundance of TGF~ 
protein, in vivo responses are more complex and fibroblasts may respond to TGFP 
secretion from many other cell types 11 8' 119. In contrast, multiple groups have shown the 
overexpression of TGF~RI and TGFPRII in SSe fibroblasts, suggesting that these cells 
are able to react to an autocrine loop and accounts for their hyper-responsiveness to pro-
fib . . 1 118-120 1 rotlc s1gna s . Others have suggested that intercellular signaling in the TGFP 
pathway may also be dysregulated. This has been shown by increased levels of total 
Smad3, increased phosphorylation and increased nuclear localization of Smad2/3 
complex, though these results are controversial 121' 122 . SSe fibroblasts display a large 
heterogeneity and cell culture conditions may vary, accounting for discrepancies between 
studies of SSe fibroblasts in vitro. While the nature of these changes in SSe fibroblasts is 
still debated, it is well established that TGFP plays a significant role in the fibrotic 
changes of SSe. 
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Figure 2: Transforming Growth Factor P Signaling. The TGFP superfamily signals 
through the action of heteromers containing Type I receptors (ALKs) and Type II 
receptors (TGFpR2, BMPR2). In addition, type III (auxiliary) receptors (beta-glycan and 
endoglin) modulate signals, are required for more efficient signaling, and in some cases, 
co-receptors may be shed as a soluble form (Sol-Endo) to sequester the ligand. Upon 
ligand binding, the Type I receptor (Alk family) becomes phosphorylated by a Type II 
receptor. Intracellular signaling is carried out by phosphorylation of receptor regulated 
(R-) Smads (Smads 1,2,3,5,8), which form oligomers with Smad4, enter the nucleus, and 
influence transcription of target genes. Canonical signaling is divided into two parallel 
pathways. Activation of Alk5/TGFPRII by TGFP ligand activates Smad2/3 signals. 
BMP ligands signal through Alk1 ,2,3 or 5/BMPR2 to activate Smadsl/5/8. In addition to 
the R-Smad family, inhibitory Smads (Smad6 and Smad7) provide an extra step of 
regulation, inhibiting Smad phosphorylation and translocation to the nucleus. In addition 
to the simplified, canonical pathway, there is extensive cross-talk between receptors and 
Smads that promote signaling of multiple pathways. (Original Publication: ten Dijke and 
Arthur 104) 
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Connective Tissue Growth Factor (CTGF) 
Connective tissue growth factor (CTGF/CCN2) is a member of the cysteine-rich 
protein "CCN" family with a high sequence homology. It contains four domains with 
homology to the proteins they are named after including: insulin-like growth factor 
binding (IGFB) domain, von Willebrand factor motif, thrombospondin type 1 repeat and 
a cysteine knot. There has been no specific receptor identified for CTGF, but it interacts 
with integrins, heparin sulfate-containing proteoglycans and the low density lipoprotein 
receptor related protein 123' 124. It is highly expressed during development and important 
for chondrogenesis, a phenotype that is obvious from the impaired bone development of 
CTGF null mice, which die shortly after birth. Little is known about the role of CTGF in 
adult tissue; it is highly expressed only during development and during pathological 
conditions such as fibrosis and carcinogenesis 125 . 
CTGF is associated with fibrotic diseases. It is known to be induced by TGF~ in 
. 
105 126 d . . . k' . . d . h TGFA 127 T . • d . f CTGF h vztro ' an m vzvo, m s m mJecte Wit 1-' • . m vzvo, m uctwn o as 
been shown in animal models of fibrosis induced by BLM in the skin 126 and lung 128 . It 
was also shown to be expressed in Type II alveolar cells and fibroblasts of the lungs in 
IPF patients 129 by lliC. In vitro and in vivo studies seem to support the conclusion that 
CTGF works synergistically with TGF~ to induce sustained fibrosis 125-127 (Figure 3). 
CTGF alone, either by injection or adenoviral expression, induces only transient fibrosis 
127
, while neutralization of CTGF was shown to protect mice from development of BLM 
induced skin fibrosis 126 . One potential mechanism for this response was shown by Mori, 
et al, CTGF null mouse embryonic fibroblasts (MEFs) were shown to have no differences 
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Figure 3. CTGF/CCN2 Signaling in Fibrosis. CTGF/CCN2 is over-expressed during 
fibrosis and required for TGF~ induced fibrosis. There is no identified receptor specific 
for CTGF /CCN2, though it has been shown to bind and signal through integrins and is 
thought to bind to and enhance signaling of TGF~. In fibroblasts , CTGF/CCN2 was 
shown to signal through av~3 integrin, inducing phosphorylation of Src and Erkl/2. 
CTGF/CCN2 was necessary for phosphorylation of Smadl but not Smad3. TGF~ 
signaling pathways further enhance expression of CTGF /CCN2 through a positive 
feedback loop involving Smadl and Etsl. (Original Publication: Nakerakanti, et a/.124) 
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in TGF~ induced signals, while there was a reduced induction of myofibroblasts 105 
This data supports the claim that CTGF is required for sustained fibrotic responses. 
CTGF is expressed in endothelial cells during development 130 and during fibrosis 
131 Developmentally, CTGF may be important for endothelial expression of PDGF-B, 
which controls interactions with pericytes and formation of the basement membrane 130 . 
The expression of CTGF in endothelial cells during fibrosis is a new area of research. In 
one publication, microvascular endothelial cells (MVECs) from SSe patients secreted 
more CTGF than MVECS from healthy donors. Upon treatment of fibroblasts with 
conditioned media from SSc-MVECs, cells displayed characteristics of myofibroblasts, 
an effect that was CTGF -dependent 131 . 
Interleukin 4 and Interleukin 13 
T helper cells may differentiate into two major subsets in response to the cytokine 
environment to which they are exposed, this process is termed "T cell skewing". The two 
major subsets are defined as Thl, responsible for pro-inflammatory reactions, and Th2 1. 
Each subset inhibits the differentiation of the other and has been implicated in certain 
pathologies. Th2 differentiation is driven by IL4, which is then further secreted by these 
cells in combination with Interleukin 13. These two cytokines have overlapping 
functions and are known to be involved in many fibrotic diseases 57 . IL4 and IL13 share 
a common IL4a receptor subunit and signal via JAK1/STAT6 pathway, which may 
partially account for their redundant functions. While IL4 binds to and signals through a 
single receptor dimer ofiL-4a/IL-2Ry, IL13 binds to either IL-13Ral/IL-4a dimer or IL-
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13Ra2/IL-4a (Figure 4). The latter is believed to function as a decoy receptor to limit the 
bioavailability of IL13, which is 10-100 times as abundant as IL4 1• New evidence 
suggests that these cytokines are not completely redundant and receptors for IL-13 may 
be preferentially expressed on non-hematopoietic cells, while IL-4 is preferentially 
d h . . 11 132 expresse on ematopmet1c ce s . 
The Th2 cytokines, IL4 and IL13, have been implicated in fibrotic diseases, 
including Scleroderma. Samples from scleroderma patients display elevated levels of 
these cytokines in serum 133' 134 and purified T cells 135 . Direct stimulation of fibroblasts 
in culture with Th2 cytokines have revealed that they function as pro-fibrotic mediators .. 
IL-13R is expressed constitutively on fibroblasts. Stimulation with IL-13 or IL-4 induces 
a TGFP-independent induction of collagen synthesis and myofibroblast differentiation in 
vitro 136' 137. Other studies have shown SSe-fibroblasts may be hyper-responsive to Th2 
cytokines due to over-expression of the IL-13R, and once stimulated, induction of TGFP 
may cause irreversible fibroblast activation 138 . In vivo studies have further confirmed a 
role of Th2 cytokines in tissue fibrosis. Expression of IL-13 is increased in BAL of 
fibrotic lungs 139, and lesional skin 140 of mice subjected to bleomycin induced fibrosis. 
Ablation of dermal fibrosis was observed in IL-13 -/-mice 134 . 
Friend-Leukemia Integration 1 (Flil) 
Fli1 (friend-leukemia integration-!) is a member of the Ets (E26 transformation 
specific) transcription factor family 141 . The family is characterized by a highly 
conserved winged helix-tum-helix DNA binding domain, termed the Ets domain 141 , 142. 
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Figure 4: IL4/IL13 Signaling. IL4 and IL 13 are Th2 cytokines that drive Th2 skewing, 
fibroblast activation, and differentiation of the M2 phenotype. Both are implicated in the 
development of fibrosis and have redundant and non-redundant functions due to shared 
receptors, which activate parallel pathways. There are two types of receptors, the Type I 
IL4R binds IL4 only, and the Type II IL4R binds both IL4 and IL13. Both receptors 
share a common IL-4Ra chain, while Type I IL-4R dimerizes with IL-2Ry and the Type 
II IL-4R dimerizes with IL-13Ral. In addition, there is an IL-13Ra2 that binds to IL-13 
only and with strong affinity. The IL-13Ra2 chain is thought to function as a decoy 
receptor as no signaling activity has been reported through binding to this receptor. Both 
Type I and Type II receptors activate the Stat6 transcription factor through action of the 
IL-4Ra chain, accounting for redundancy in signaling through IL-4 and IL-13 cytokines. 
In addition to these overlapping functions, the dimerization partner for both receptor 
types has its own activity, accounting for their distinct functions. (Original publication: 
Gordon and Martinez 132) 
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This Ets domain, named after the first identified member (Etsl), recogmzes a core 
sequence within target genes via a consensus site of GGA(A/T) that are referred to as Ets 
B. d. s· (EBS) 142 143 m mg 1tes ' . The closest homolog to Flil is Erg, believed to have 
redundant functions as a result of duplication in the genome 141 . Flil was originally 
described as a proto-oncogene in a mouse model of erythroleukemia 144 and later 
identified for its role in the human pediatric tumor, Ewing sarcoma 145' 146 . As a 
hematopoietic transcription factor, it is most highly expressed in immune and endothelial 
cells where it has been shown to have a role in growth and differentiation. Fli 1 is 
expressed at much lower levels in fibroblasts where it has been shown to have an 
important role in the regulation of collagen and tissue fibrosis 106. 
Flil was originally described to contribute to a B cell phenotype in systemic lupus 
erythematosus (SLE). Over-expression of Flil was shown in PBMCs of patients with 
SLE and in the MRL/lpr mouse model of lupus 147 . In a mouse model of SLE, a 50% 
down-regulation of Flil was protective against renal pathology and lowered IgG levels 
and anti-dsDNA levels in serum 148. To determine whether Flil was affected in another 
autoimmune disease, SSe, immunostaining of Flil in SSe dermal biopsies was compared 
to levels in normal skin. Flil was reduced in endothelial cells and fibroblasts in SSe 
patient biopsies. Interestingly, comparison between lesional and uninvolved skin from 
SSe patients show that uninvolved skin is intermediate between lesional and normal skin 
in terms of Flil expression. Similar results were shown in cultured dermal fibroblasts 
from SSe patient biopsies, showing decreased expression ofFlil protein 149 . 
38 
In SSe dermal fibroblasts, Flil expressiOn is negatively correlated with the 
expression of collagen, a relationship that was shown further in Flil~/-, Flil+/- and 
Flil +/+ MEFs. Overexpression of Flil in fibroblasts was shown to decrease the 
transcription of collagen-a2(I), and conversely, knockdown of Fli1 by siRNA increases 
the expression of type I collagen. This suggests that Fli1 is a repressor of collagen I 
transcription and synthesis. In addition to the control of collagen, Flil exerts further anti-
fibrotic effects through the control of Connective Tissue Growth Factor (CCN2/CTGF). 
The balance of Flil and Ets1 seems to be important in fibrosis. Through competition 
experiments, it was shown that Fli1 and Etsl have antagonistic effects on the Colla2 
promoter 150. This balance is regulated by the master regulator of fibrosis, TGF~. 
Upon TGF~ stimulation, Flil protein content decreases in a time dependent 
manner with no changes m mRNA levels, suggesting TGF~ regulation by a post-
translational mechanism 151 TGF~ stimulation induces activation and nuclear 
translocation of Protein Kinase C 8 (PKC8) through a Smad independent action. PKC8 
is then able to phosphorylate Fli 1 on Threonine 312, which allows a subsequent 
acetylation at Lysine 380 by p300/CBP Associated Factor (PCAF) 152 . Current evidence 
suggests that acetylation ofFlil allows recognition by an unidentified E3 ubiquitin ligase 
and subsequent ubiquitination and degradation 152. 
Investigation of the role of Fli 1 in a mouse model of fibrosis is hindered by the 
fact that a complete Flil knockout is embryonic lethal due to a hemorrhagic phenotype 
153
. Investigation of a partial Fli 1 deletion, in which the C-Terminal Transactivation 
Domain (CTA) responsible for protein-protein interactions was removed, showed 
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impaired fibrillogenesis. mRNA levels of the collagen chains (Coil al, Coil a2, Col3al, 
Col5al, and Col5a2) were significantly increased and there was a significant increase in 
collagen protein level by the pepsin/acetic acid method. Collagen fibrils were examined 
by electron microscopy and showed large diameters, irregular shapes and a wide range of 
sizes, but histologically there was no change in skin thickness 154. This model has 
confirmed the role ofFlil in the in vivo regulation of collagen synthesis and is suggestive 
of a role for Flil in dermal fibrosis. It still needs to be determined whether Flil down-
regulation is a universal process in the development of fibrosis and whether Flil is altered 
in fibrotic tissue of other organs. 
Little is known about the role of Flil in endothelial cells and the effects of its 
down-regulation in human SSe patients, however, progress has been made using a Flil 
endothelial cell specific knockout of Flil (Flil CKO). This Flil CKO mouse displays a 
vascular phenotype with leaky vessels 155 , suggesting a role for Fli 1 in the maintenance of 
vascular integrity. Though these results are promising, more work needs to be done to 
determine ifFlil plays a role in vasculopathy in the pathogenesis ofSSc. 
An upcoming cell type of interest from our studies involves the role of Fli 1 m 
macrophages. One publication has shown that Fli 1 is highly expressed in these cells and 
regulates the production of the anti-inflammatory cytokine IL-10 and expression of 
certain MMPs 156 . The role of Flil in macrophages, fibroblasts and endothelial cells 
suggests that this transcription factor may regulate fibrotic processes in multiple cell 
types. 
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MATERIALS AND METHODS 
Animal Model 
Pulmonary fibrosis was induced in 8-12 week old male C57BL/6 mice (Charles 
River Laboratories). Animals were injected daily with lOO!lL of bleomycin (1mg/mL, 
Enzo Life Sciences, Farmingdale, NY, USA) or saline control by subcutaneous route for 
7,14 or 28 days. Mice were euthanized 24h after the final treatment. 
Tissue Collection/Histology 
For histology, mice were sacrificed by C02 followed by cervical dislocation. 
Mice were shaved around the area of injection and 6mm skin punch biopsies were taken 
from around the area of injection. The opposite side of the animal was shaven for skin 
biopsy from a. distal area. The right lung was tied off and saved in RNA later (Life 
Technologies, Grand Island, NY, USA). The left lung was infused with 4% 
paraformaldehyde through the trachea and fixed overnight at 4°C. Tissues were then 
transferred into 70% ethanol overnight and dehydrated in a graded series of ethanol 
solutions and xylene prior to embedding in paraffin blocks. For histology, 4-Silm 
sections were stained by H&E (Hematoxylin: Ricca Chemical; Eosin: Fisher), Gomori ' s 
Trichrome (Chromaview) or used for Immunohistochemistry. 
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Immunohistochemistry of Mac3 and vWF 
Tissue sections were deparaffinized and rehydrated through a series of washes in 
Histo-clear followed by decreasing concentrations of ethanol. Antigen retrieval was 
carried out by boiling slides in antigen unmasking solution with citrate buffer (pH 6.1) 
and allowed to cool on the bench top. Fe receptor was blocked for 30 minutes at room 
temperature using Fe Receptor Block (Innovex). Endogenous peroxidase activity was 
blocked by incubating slides at room temperature for 30 minutes in 0.3% hydrogen 
peroxide. Slides were washed in 1x PBS and incubated in 0.1 M glycine for 45 minutes 
at 4°C (Mac3 only). Blocking was carried out in 3% n01mal rabbit serum (Mac3) or 3% 
normal goat serum (vWF) for 1h at room temperature. Slides were incubated overnight 
with rat anti-mouse Mac3 (1 :50; BD Pharmingen) or rabbit anti-human vWF (1: 1200; 
Dako) in normal serum. Slides were incubated in biotinylated rabbit anti -rat (1 :2000; 
Mac3) or biotinylated goat anti-rabbit (1 :500; vWF) for 30 minutes at room temperature. 
To visualize staining, the ABC and DAB Substrate kits were used according to the 
manufacturer's protocol (Vector). Slides were counterstained in hematoxylin (Richard 
Allan Scientific), dehydrated and mounted using cytoseal (Richard Allan Scientific). 
Immunohistochemistry of Flil 
For Fli1 staining, slides were blocked in Fe blocker (Innovex Biosciences, 
NB309-15) following hydrogen peroxide. A 1:13 dilution of donkey anti-goat Fab 
fragments (Jackson ImmunoResearch 715-007-003) diluted in 5% BSA was used for 
blocking. Antibodies were then diluted in 5% BSA. A 1:100 dilution of mouse anti-
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human Fli1 (BD Pharmingen, 554266) was used as a primary and a 1:1000 dilution of 
Mouse IgG was used as an isotype control (Jackson ImmunoResearch 015-000-003). A 
1:400 dilution of Biotinylated Fab Donkey Anti-Mouse (Jackson Immunoresearch 715-
067-003) was used as a secondary antibody. 
Flow Cytometry/Cell Sorting 
Lung tissue was digested by mechanical disruption with a razor blade, followed 
by enzymatic digestion for lh at 37°C in a 0.01% collagenase 1/Dispase solution with 
CaCh. Suspension was passed through a 70J..lm filter to remove debris, centrifuged and 
re-suspended in FACS buffer (0.3% PBS, 2f.!M EDTA in 1x PBS). Cells were incubated 
on ice for 10 minutes in Fe block followed by immunostaining for 30 minutes with 
APC-labeled CD45 and PE-labeled CD31. Stained cells were washed and sorted by 
flow cytometry (MoFlo, Beckman-Coulter) to separate the endothelial (CD45- CD31 + ), 
immune cell (CD45+ CD31-) and parenchymal (CD45- CD31-) populations (Figure 4). 
In a separate experiment, cells were sorted by the methods described above using APe-
labeled CD11c and PE-labeled CD11b for staining of macrophage and dendritic cell 
subpopulations. 
For isolation of RNA, cells were immediately lysed in buffer RL T (Qiagen) with 
the QIAshredder column (Qiagen). RNA was isolated by the RNeasy Mini Kit (Qiagen) 
and Real Time qRT -PCR was perfmmed as described below. 
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Real Time Quantitative PCR 
One microgram of RNA was reverse transcribed in a 20-fll. reaction using random 
hexamers. Analysis of a subpopulation of cells was canied out by Cell Sorting 
(described above) followed by a eDNA amplification step using the Ovation PicoSL 
WTA V2 kit (NuGEN Technologies Inc., San Carlos, CA). Quantitative (q)-PCR was 
canied out using SYBR Green PCR Master Mix (Applied Biosystems) on a 
StepOnePlus Real-Time PCR System (Applied Biosystems) using 1 fll of diluted eDNA 
in triplicate, with ~-actin as the internal control. The primers used are as listed in Table 
1. Results were normalized to a saline injected control lung and fold change was 
reported using the 1'11'1Ct method using ~actin as an internal control. Statistics are 
reported as a two-tailed, unpaired Student's t-test. 
Isolation of Bone Marrow Derived Macrophages 
C57Bl/6 mice were sacrificed by C02 followed by cervical dislocation. Tissue 
and instruments were sterilized with alcohol and the tibia and femur were cleaned of hair, 
skin and muscle tissue. Using scissors, a cut was made above the femur and bones were 
placed in sterile PBS. All further steps were carried out under sterile conditions. Once 
bones were completely cleaned of tissue, the tibia and femur were separated from the 
joints and cleaned with ethanol. A cut was made on either end of each bone and each 
was flushed using 25g needle and l OmL of DMEM under sterile conditions until bones 
appeared white. Marrow was centrifuged at 1500rpm for 5 minutes and red blood cells 
were lysed using 500)lL of sterile red blood cell lysis buffer (Sigma R7757) and 
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centrifuged once again. The pellet was resuspended in DMEM, strained through a 70f.!M 
strainer (BD 352350) and centrifuged a final time. Cells were counted using a 
hemacytometer and plated at a concentration of 2x106cells/mL in DMEM supplemented 
with 10% L929 supernatant (a generous gift from the lab of Dr. Ian Rifkin), 10% FBS 
and antibiotics. Macrophages were differentiated over a total of six days in media 
supplemented with L929 supernatant, with the addition of fresh media on the fourth day. 
On the sixth day, cells were re-plated at a density of 2x106 cells/mL and stimulated the 
following day. 
Culture of RAW Cells 
RAW cells were a generous gift from the lab of Dr. Gerald Denis. Cells were 
maintained in DMEM supplemented with 10% FBS and antibiotic-antimicotic solution. 
Cells were passaged by dislodging using a cell scraper and subcultured at 1:10-1:20. 
Isolation and culture of human pr·imary fibroblasts 
Human dermal fibroblast cultures were established from biopsy specimens 
obtained from the dorsal forearms of healthy donors, upon informed consent and in 
compliance with the Institutional Review Board. Dermal fibroblasts were isolated from 
enzymatic dissociation of tissue in 20% fetal bovine serum (FBS), 0.25% collagenase 
type I (Sigma) and 0.05% DNase (Sigma) in Dulbecco' s modified Eagle's medium 
(DMEM). Digestion medium was maintained at 37°C with gentile shaking until tissue 
was digested Fibroblasts were maintained in DMEM supplemented with 10% FBS and 
1% antibiotic-antimycotic solution and passaged using a solution of 0. 025% Trypsin. 
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Fibroblasts were incubated in serum-free medium (DMEM, 0.1% bovine serum albumin) 
for 24h prior to treatment. SSe dermal fibroblasts were age and gender matched with 
controls. 
Adenoviral siRNA Vector 
The following siRNA target sequence was used for Fli1, GTTCACTGCTGGCC-
T AT AA. Annealed double-stranded oligonucleotides were cloned into Mlul and Xhol 
sites of pRNAT -H1.1 shuttle vector (Genescript). The shuttle vector plasmid and 
Adenoeasy vector plasmid were sequenced to confnmthecloning. The shuttle vector with 
target siRNA sequence was linearized with Pmel and then electroporated into BJ5183-
AD-1 (Stratagene) to generate recombinant Adenoeasy vector. The recombinant 
Adenoeasy plasmid after linearization with Pacl enzyme was transfected into QBI-293 
cells using Transfectin (Bio-Rad) for generation of adenovirus. The primary adenoviral 
stock was then amplified and concentrated by cesium chloride density gradient 
centrifugation. Control adenovirus vector (SCR) was prepared in the same manner. 
Immunoblotting 
Total cell lysate was prepared by resuspending a cell pellet in lysis buffer (20 mM 
Tris-HCl, pH 7.5, 15 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 
sodium pyrophosphate, and 1 mM glycerophosphate with freshly added protease and 
phosphatase inhibitors (Sigma Aldrich)) and incubated for 20 minutes on ice. For 
experiments where separation of nuclear and cytoplasmic components was necessary, the 
NE-PER Kit (Pierce) was used according to manufacturer's protocol. 
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Protein concentration was quantified using the BCA Protein Assay kit (Pierce), 
according to manufacturer protocol. Equal amounts of protein for each sample were 
separated on a 10% acrylamide gel via SDS-P AGE and transferred to nitrocellulose 
membranes (Bio-Rad). Membranes were blocked in 3% milk in TBST for 1 h and 
incubated with primary antibody (mouse anti-human Fli1 BD Pharmingen, 554266; 
rabbit anti-human TIMP3 : Millipore, AB6000) at a concentration of 1: 1000 overnight at 
4°C diluted in 3% milk. Membranes were probed with HRP-conjugated secondary 
antibody against the appropriate species (sheep anti-mouse HRP: GE Healthcare, 
NXA931; goat anti-rabbit HRP: GE Healthcare, RPN4301) at 1:5000 for 1h at room 
temperature. Protein was visualized using ECL reagent (Pierce). As a loading control, 
membranes were stripped using Restore Western Blot Stripping Buffer (Pierce) and re-
probed using a 1:2500 dilution of mouse monoclonal anti-P-actin (Sigma, A5441) and 
1:10,000 dilution of sheep anti-mouse as a secondary. 
Microarray 
MouseGenel.OST array was run by the Boston University School of Medicine 
Microarray Core Facility. Statistical analysis was done by Dr. Adam Gower, as follows. 
Raw Affymetrix CEL files were normalized to produce gene-level expression values 
using the implementation of the Robust MultiaiTay Average (RMA) 157 in the affy 
package 158 included within in the Bioconductor software suite (version 2.1 0. 0) 159 and an 
Entrez Gene-specific probeset mapping from BrainArray (version 14.0.0) 160. Microarray 
normalization was performed using the R environment for statistical computing (version 
2.12.0) 
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Figure 5: Gating strategy for CD31+CD45- cell sorting. A single cell suspension from 
the lung was blocked using Fe blocker over ice for 10 minutes followed by 30 minutes 
staining in CD31/PE and CD45/ APC in the dark. Cell sorting was done by the core 
facility at Boston University School of Medicine. Cells were gated to eliminate (A) 
debris and (B) doublet cells. The following controls were used to set further gates: (C) 
unstained, (D) APC single stain and (E) PE single stain. Double stain (F) is shown as a 
representative image. 
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Table 1: Primers used for real-time quantitative PCR (qRT-PCR) 
Forward Reverse 
Bactin AAGGCCAACCGTGAAAAGAT GTGGTACGACCAGAGGCATAC 
Collal GCCAAGAAGACATCCCTGAAG TGTGGCAGATACAGATCAAGC 
Colla2 GCCACCATTGATAGTCTCTCC CACCCCAGCGAAGAACTCATA 
Col3al TTTGTGCAAGTGGAACCTG TGGACTGCTGTGCCAAAATA 
Col5al GGACTAGTCCGCTTTCCCTGTCAACTT GTGGTCACTGCGGCTGAGGAACT 
GTCCGATGG TC 
Col5a2 CAGAAGCCCAGACGTATCG GGTGGTCAGGCACTTCAGAT 
Pail AGGATCGAGGTAAACGAGAGC GCGGGCTGAGATGACAAA 
Ctgf TGACCTGGAGGAAAACATTAAGA AGCCCTGTATGTCTTCACACTG 
lfgfj31 TGGAGCAACATGTGGAACTC CAGCAGCCGGTTACCAAG 
Mcpl/Ccl2 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAGT 
Emrl CCTGGACGAATCCTGTGAAG GGTGGGACCACAGAGAGTTG 
vWF CCAAGGAGGGTCTGCAACT AAAGGAAGACTCTGGCAAGCTA 
Mmp12 TGATGCTGTCACAACAGTGG GTAATGTTGGTGGCTGGACTC 
Icaml CCCACGCTACCTCTGCTC GATGGATACCTGAGCATCACC 
Yearn iATGGAATCTGAACC CCCAGATGGTGGTTTCCTT 
E-selectin TCCTCTGGAGAGTGGAGTGC GGTGGGTCAAAGCTTCACAT 
P-selectin ATGCCTGGCTACTGGACACT GACTGAGCATAGGGGCACA 
Cd34 GGGTAGCTCTCTGCCTGATG TCCGTGGTAGCAGAAGTCAA 
Cxcll AGACTCCAGCCACACTCCAA TGACAGCGCAGCTCATTG 
Cxcl2 AAAATCATCCAAAAGATACTGAACAA CTTTGGTTCTTCCGTTGAGG 
Ccl3 TGCCCTTGCTGTTCTTCTCT GTGGAATCTTCCGGCTGTAG 
Ccl6 TCTTTATCCTTGTGGCTGTCC TGGAGGGTTATAGCGACGAT 
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Ccl7 TTCTGTGCCTGCTGCTCATA TTGACATAGCAGCATGTGGAT 
Ccl9 TGGGCCCAGATCACACAT CCCATGTGAAACATTTCAATTTC 
C3aR GTGGCTCGCAGATCATCA AAGACTCCATGGCTCAGTCAA 
CSaR GCATCCGTCC£TCrt1TTAC TGCTGTTATCTATGGGGTCCA 
IL6 GCTACCAAACTGGATATAATCAGGA CCAGGTAGCTATGGTACTCCAGA 
A 
Osm TGCTCCAACTCTTCCTCTCAG CAGGTTTTGGAGGCGGATA 
Lif AAACGGCCTGCATCTAAGG AGCAGCAGTAAGGGCACAAT 
Fibronectin TGGGTCTGAGTACACCGTGA GTGGAATGGAGCGCAGAG 
Fspl GGAGCTGCCTAGCTTCCTG TCCTGGAAGTCAACTTCATTGTC 
Ve-Cad GGCAATCAACTGTGCTCTCC CTTCGTGGAGGAGCTGATCT 
Cd31 CGGTGTTCAGCGAGATCC CGACAGGATGGAAATCACAA 
Jam2 GAACCTGCAGGAAGATAAAGTCA GCACTTCACAGGCAGGAAC 
Claudin5 ACGGGAGGAGCGCTTTAC GTTGGCGAACCAGCAGAG 
Et-1 CTGCTGTTCGTGACTTTCCA TCTGCACTCCATTCTCAGCTC 
Ecel CCCTGATGGAGCTGATTGA GTCCTGGAAGTTGTCCTTGG 
eNos CCAGTGCCCTGCTTCATC GCAGGGCAAGTTAGGATCAG 
Il-l TTGGTTAAATGACCTGCAACA GAGCGCTCACGAACAGTTG 
Tnfa. TCTTCTCATTCCTGCTTGTGG GGTCTGGGCCATAGAACTGA 
OPN CCCGGTGAAAGTGACTGATT TTCTTCAGAGGACACAGCATTC 
Tn-c GGGCTATAGAACACCGATGC CATTTAAGTTTCCAATTTCAGGTT 
c 
Timp l GCAAAGAGCTTTCTCAAAGAC AGGGATAGATAAACAGGGAAAC 
ACT 
Timp2 CGTTTTGCAATGCAGACGTA GGAATCCACCTCCTTCTCG 
Timp3 CACGGAAGCCTCTGAAAGTC TCCCACCTCTCCACAAAGTT 
so 
hGapdh GGTCTCCTCTGACTTCAACA AGCCAAATTCGTTGTCATTAC 
hFlil GGATGGCAAGGAACTGTGTAA GGTTGTATAGGCCAGCAG 
hTimp3 TGCAACTCCGACATCGTG AAGGGCCCCTCCTTTACC 
*Unless otherwise stated, pnmer sequences are for mouse 
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CHAPTER 3: Endothelial cells recruit macrophages and contribute to a fibrotic 
environment in lung injury 
PURPOSE 
Systemic Sclerosis (SSe) is a progressive autoimmune disease characterized by 
vascular abnormalities, immune dysfunction and fibrosis of skin and internal organs. 
Pathogenesis of SSe is not completely understood but is believed to be initiated by an 
early and persistent damage to the endothelium, which may initiate inflammation and 
activation of fibroblasts, resulting in excess deposition of collagen. The most common 
model to study pulmonary fibrosis uses the antibiotic and chemotherapeutic drug, 
Bleomycin (BLM). Administration of the drug to rodents has become a useful model to 
study interstitial lung diseases. BLM is typically delivered by intratracheal instillation, 
targeting epithelial cells and resulting in pelibronchial and peribronchiolar fibrosis. 
Injection through subcutaneous or intravenous routes results in perivascular and 
subpleural fibrosis which may more closely resemble human interstitial lung disease 
(ILD) 40. Similar to SSe, endothelial cells aTe believed to be a primary target of 
bleomycin when administered subcutaneously 161 and have been shown to undergo 
. 1 ft . . 41 42 d . . 43 Th h d h 1i 1 ll apoptos1s ear y a er treatment 111 VIvo ' an 111 VItro . oug en ot e a ce s are 
likely targeted by BLM, the extent to which endothelial cells contribute to pulmonary 
inflammation and fibrosis and the extent of vasculopathy in this model are debated 
BLM administration to rodents is used to study ILD in patients with SSe and in IPF. We 
chose a subcutaneous administration route developed by Yamamoto, which induces a 
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SSe-like skin disease and pulmonary changes, reproducing two of the most characteristic 
features of SSe 37' 162. We hypothesized that endothelial damage during BLM 
induced pulmonary fibrosis correlates with the pathogenesis of fibrosis. To test this 
hypothesis we used a method of cell sorting and subsequent gene expression analysis 
which can accurately detect the regulation of genes in an isolated cell population. 
AIMl: Establish subcutaneous model of bleomycin induced lung injury. We aim to 
determine A the localization and time-course of inflammation and fibrosis after 
subcutaneous injection of BLM and B. the resemblance of this model to SSc-ILD. We 
determined that mice injected with bleomycin for 28 days developed an inflammatory 
response shown by increased cellularity in H&E stain of lung tissue. Further analysis of 
macrophage infiltration was done by immunohistochemistry (IHC) of Mac3 and F ACS 
using CDllb and CDllc macrophage markers . Pulmonary fibrosis with perivascular and 
subpleural localization, similar to human ILD, was examined by measurement of 
collagen deposition using trichrome stain of lung tissue and mRNA expression of 
interstitial collagen genes by qRT-PCR (Collal, Colla2, Col3al, Col5al, Col5a2). 
AIM2: Characterize the response of endothelial cells to lung injury. Damage of 
endothelial cells is believed to be an initiating process in the development of SSe, we 
aimed to determine the contribution of endothelial injury in inflammation and fibrosis in 
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the BLM mouse model of pulmonary fibrosis. Pulmonary endothelial cells from BLM or 
PBS injected animals were sorted by FACS, RNA was extracted from CD31+ CD45-
cells for analysis of gene expression using microarray, and confirmation was done by 
qPCR. Endothelial damage was indicated by markers for vascular injury, Mmp 12 and 
von Willebrand Factor (vWF), with confirmation of vWF by IHC. The role of ECs in 
inflammation was identified by gene expression of adhesion molecules (Intercellular 
Adhesion Molecule 1 (Icam1 ), Vascular Cell Adhesion Molecule 1 (V cam), E-selectin, 
P-Selectin, Cd34), chemokines (Cxcll, Cxcl2, Ccl2, Ccl3, Ccl6, Ccl7, Ccl9), 
anaphylatoxin receptors (C3aR, C5aR) and IL 6 family of cytokines (Leukocyte 
Inhibitory Factor (Lif), Oncostatin M (Osm), Interleukin 6 (116)). Endothelial cell 
contribution to fibrosis was detemrined by expression of fibrogenic mediators 
(Connective Tissue Growth Factor (Ctgf), Transforming Growth Factor ~ (Tgfl3), 
Plasminogen Activator Inhibitor (Pai-l), Osteopontin (OPN)) and endothelial to 
mesenchymal transition markers (Fibroblast Specific Protein 1 (Fsp 1 ), Fibronectin 
(Fnl)). As a measure of potential vasculopathy in the SSe model, we quantified adhesion 
molecules involved in maintenance of vascular integrity (Vascular Endothelial Cadherin 
(Ve-cadherin), Cd31, Junctional Adhesion Molecule 2 (Jam2), Claudin 5) and expression 
of vascular mediators (Endothelin 1 (Et-1), Endothelin Converting Enzyme 1 (Ecel), 
Endothelial Nitric Oxide Synthase (eNos)). 
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RESULTS 
Dermal fibrosis in BLM injected mice 
Subcutaneous instillation of BLM has been reported to more closely resemble 
human ILD 40. We chose a 28 day injection model developed by Yamamoto, et al 37 , 
which induces a Scleroderma-like dermal fibrosis as well as pulmonary fibrosis. To 
determine the efficacy of the daily bleomycin injection, we used H&E stain to visualize 
thickness of the dermal layer as a measure of skin fibrosis (Figure 6). Two biopsies were 
taken from each animal, a local biopsy near the injection site on the right side and a distal 
biopsy from the left side, to determine whether changes in skin were local or systemic. 
The local biopsy from PBS injected mice appeared histologically normal, with normal 
thickness of the dermal layer, fat layer, muscle and hypodermis. In the BLM injected 
animal, skin around the injection site showed thickening of the dermal and hypodermal 
layers with loss of fat and muscle. A biopsy from a distal site in the BLM injected mouse 
showed normal skin histology, similar to the local PBS injected skin. Next, we wanted to 
determine whether subcutaneous bleomycin injection had systemic effects on the mice. 
Weight loss in BLM injected mice 
Weight loss after injection by bleomycin in mice has been shown to correlate with 
pulmonary fibrosis and is suggested to be driven by an inflammatory driven cachexia. 163 . 
Mice were weighed on a weekly basis to monitor the overall health and as a measure of 
the drug's effects on the animals over the projected time-course. Weight loss was 
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PBS BLM, local BLM,distal 
Figure 6: Subcutaneous injection of BLM induces local dermal thickening. Mice on 
a C57Bl/6 background were injected daily with lOOJlL of BLM (lmg/mL) or saline 
(PBS). A skin biopsy was taken at the injection site (local) for the BLM and PBS groups. 
In the BLM injected animal, a second biopsy was taken from an anatomically similar 
location on the opposite side of the animal (distal) for comparison. Thickened dermis is 
represented by black bar (BLM, local) compared to control (PBS). (representative 
images, n=4) 
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suggestive of systemic effects that lead to pulmonary inflammation and fibrosis . Mice in 
the BLM treated group progressively lost weight, showing a significant difference to the 
saline control group by the first week, which was sustained throughout the experiment 
(Figure 7). Ultimately, our goal was to describe effects of subcutaneously administered 
bleomcyin on the lungs of mice, with a concentration on the role of endothelial cells. To 
determine the effects of BLM on the lungs, we next examined histology of the lungs and 
immune cell infiltration. 
Inflammation in lungs of mice after daily subcutaneous BLM administration 
Inflammation is believed to drive the begi1ming stages of skin fibrosis in SSe and 
lung fibrosis in IPF and SSe 11' 23 . In the bleomycin model of pulmonary fibrosis, 
infiltration of neutrophils, macrophages and T cells is noted prior to the development of 
fibrosis 35' 36. To determine the time-course and progression of pulmonary inflammation, 
a standard H&E stain in lung sections was used to determine the cellularity of tissue and 
general histological appearance within the first two weeks (Figure 8). To determine 
whether lungs were affected in the PBS administered group, lungs were compared to an 
uninjected, na'ive animal. H&E stained lungs from a na'ive animal have limited cellularity 
(Figure 8A) and thin alveolar walls (Figure 8B). Lungs of PBS injected mice at 14 days 
had no changes in cellulmity (Figure 8C) or alveolar thickness (Figure 8D) when 
compared to a nai've animal, suggesting that subcutaneous PBS injections had limited 
effects on the lung. As early as 4 days in the BLM injected group, lungs appeared to 
have greater cellularity (Figure 8E), suggesting inflammation, which was slightly 
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Figure 7: Subcutaneous injection of BLM induces weight loss in C57Bl/6 mice. 
C57Bl/6 mice were injected daily with lOOJ.ll of bleomycin (1mg/mL) or saline (PBS) 
and weighed on a weekly basis throughout the experiment. (n=S-12, **p ::::; 0.01, ***p ::::; 
0.001) 
58 
A. Naive(40x) 14d, PBS (40) 14d, PBS (200x) 
E. 
Figure 8: Subcutaneous injection of BLM induces pulmonary inflammation. C57Bl/6 mice were injected daily 
with lOOul of bleomycin (lmg/mL) or saline (PBS). Mice were sacrificed and the left lung was fixed by tracheal 
perfusion for histological analysis of inflammation by H&E. Results are representative images of the following 
groups: Naive (A-B), 14d PBS (C-D), 4d BLM (E-F) and 14d BLM (G-H). Images are low magnification (40x: 
A,C,E,G) or high magnification (200x: B,D,F,H). 
resolved by day 14 (Figure 8G). Upon closer examination at 4 days (Figure 8F), alveolar 
walls were thickened with an increase in nuclear staining. At high magnification of lungs 
injected with BLM for 14 days, alveoli were collapsed in some areas of the lung (Figure 
8H). In the representative image shown, collapsed alveoli are located around a blood 
vessel (black arrow). In conclusion, the inflammatory response was induced early and 
persisted into the second week. We next aimed to determine the time-course leading to 
development of pulmonary fibrosis . 
Pulmonary fibrosis is induced in mice after daily subcutaneous BLM adminsitration 
Fibrosis induced by subcutaneous administration of BLM has been shown to have 
a histological localization similar to ILD in humans, with fibrosis beginning as 
perivascular and sub-pleural lesions 40. To measure fibrosis in lung tissue and determine 
the time-course of events, we used Gomori 's Trichrome stain as histological measure for 
collagen deposition. This stain is specific for collagen, which stains blue against a pink 
background (cytoplasm/muscle stain). As a counterstain, nuclei are stained black by 
hematoxylin. We hypothesized that fibrosis would begin to develop around the second 
week, as alveolar collapse was first noted around this time in the H&E stain. The 
histological appearance of lungs from PBS injected animals was similar for the trichrome 
stain as the H&E stained samples, with normal architecture and thin alveolar walls 
(Figure 9A,B). In the lungs of PBS injected animals, collagen deposition was limited to 
the area around larger airways. Within the BLM injected animals, fibroblastic foci in 
lungs were observed as early as 14 days with a subpleural localization (Figure 9C,D). 
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Figure 9: Subcutaneous injection of BLM induces pulmonary fibrosis. C57Bl/6 mice 
were injected daily with BLM or saline (PBS). The left lung was fixed by tracheal 
perfusion and the right lung was saved in RNA later. (A) Histological analysis of 
collagen deposition was measured by Gomori ' s trichrome stain of na"ive, 14d BLM, and 
28d BLM (E,F) lung sections. Results are shown as low magnification ( 40x) or high 
magnification (200x). (B) Collagen synthesis was confirmed by qRT-PCR of interstitial 
collagens (Collal , Colla2, Col3a1 , Col5a1 and Col5a2) of whole tissue extract. Relative 
expression is quantified by the ~~Ct method and represented as a fold change, 
normalized tissue from lungs of a na"ive animal. Student's two-tailed, unpaired t-test 
compared BLM samples to saline injected samples at the same time-point. (n=3-4, *p :S 
0.05, **p :s 0.01 , ***p :s 0.001) 
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Fibrotic regions were substantially larger by day 28 in lungs of ELM-treated mice (Fig 
9E) and show complete obliteration of the alveolar compartment (Figure 9F). As a 
second measure of collagen deposition of the lung, qPCR was used to quantify interstitial 
collagens and validate that collagen is being actively synthesized. Interstitial collagens 
(Collal, Colla2, Col3al , Col5al, Col5a2) constitute over 95% of the total collagen 
content of the lung and are increased during fibrosis 164. All interstitial collagen chains 
were increased significantly at both 2 and 4 weeks, and correlated with the timing of the 
histological appearance of fibrosis (Figure 9G). These results confirm the presence of 
pulmonary inflammation and fibrosis in a chronic model of lung injury after systemic 
bleomycin administration. While many cell types are implicated in fibrosis, macrophages 
are an important cell type and secrete many pro-inflammatory and pro-fibrotic molecules . 
To further characterize the effect of subcutaneous bleomycin administration on the 
development of fibrosis, we examined lung tissue for the presence ofmacrophages. 
Macrophage infiltration in lungs of mice after daily subcutaneous BLM 
Fibrosis is believed to result from an injury response, with macrophage 
recruitment as a central cell type in inflammatory driven fibrosis 58. We investigated the 
infiltration of macrophages to the lung after injury by subcutaneous BLM. We 
hypothesized that macrophage recruitment was early, prior to the development of 
fibrosis. To observe the presence and localization of macrophages in tissue, we used 
immunohistochemistry to detect the Mac3 antigen, a general macrophage marker first 
identified on peritoneal macrophages165. Macrophages were observed within the alveolar 
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and interstitial spaces of ELM -treated mice by the second week and increased further in 
number by the fourth week (Figure 1 OA) and correlated with the timing of fibrosis 
(Figure 9). As an additional measure of macrophage recruitment, qPCR was used to 
quantify the level of macrophage markers within the total lung tissue. CCL2/MCP1 is a 
main chemotactic factor for macrophage recruitment 166 and was significantly increased 
at the mRNA level in tissue from ELM-injured lungs two weeks after treatment. 
Ccl2/Mcp1 expression steadily increased from the first week, reaching the highest 
induction in the fourth week (Figure 1 OE). In addition, we quantified gene expression of 
Emr1, a marker expressed on macrophages. Emr1 was increased in total lung 
homogenate from ELM-treated mice in the fourth week (p=0.05119, Figure 10C). We 
next aimed to quantify the numbers ofmacrophages within lung tissue of ELM-treated 
m1ce. 
Sub populations of macro phages in lungs of mice after BLM-injwy 
Within the lung, there are subpopulations of macrophages. Alveolar macrophages 
reside within alveolar spaces and clear inhaled particulate, avoiding injury to the lung. 
These macrophages are a resident population and different from interstitial macrophages 
. h . . f ~ k 24 59 A . . f h m t eu expressiOn o sur1ace mar ers ' . s a quantitative measure o macrop age 
infiltration, we used flow cytometric cell sorting (F ACS) to determine relative changes 
within cell populations of the lung (represented as a percentage). In addition, total cells 
were counted from the F ACS Aria from a single cell suspension of lung cells. It was 
hypothesized that there would be an increase in macrophage cell populations in the lung 
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Figure 10: Subcutaneous BLM injection induces infiltration of macrophages. 
C57Bl/6 mice were injected daily with BLM or saline (PBS). The left lung was fixed by 
tracheal perfusion and the right lung was saved in RNA later. Macrophage numbers were 
increased in tissue in 2wk and 4wk in BLM mice, shown by IHC of Mac3 (A) shown at 
high magnification, with nuclei stained by hematoxylin (200x, scale bar = 50f.!m). The 
presence of macrophages in the lung were analyzed by qRT-PCR of total tissue extract 
for Mcpl /Ccl2 (B) and Emrl (C), relative expression was normalized to normal (saline 
injected) lung tissue. Relative expression is quantified by the ~~Ct method and 
represented as a fold change, normalized tissue from lungs of a na'ive animal. Student' s 
two-tailed, unpaired t-test compared BLM samples to saline injected samples at the same 
time-point. (n=3-4, *p :::; 0.05, **p:::; 0.01) 
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after BLM treatment. We determined that there was a significant increase in percentage 
(Figure llA) and absolute number (Figure llB) of interstitial Macrophages (COllb+ 
COlle-) and dendritic cells (COllb+ COlle+) at both two and four weeks of ELM-
treatment. Conversely, percentage and absolute number of alveolar macrophages 
(COllb- COlle+) was decreased at both time points (Figure 11). Images are 
representative from multiple experiments, and table 2 shows that changes in the percent 
of cell populations were statistically significant. Upon characterization of the 
inflammatory and fibrotic response in lungs exposed to BLM, we aimed to determine the 
response of endothelial cells by gene expression analysis. 
Injwy of pulmonary endothelial cells in mice exposed to daily subcutaneous BLM 
It is believed that endothelial injury and apoptosis may contribute to the 
pathogenesis of fibrotic skin and lung disease 15 ' 167' 168 . Much of what is known about the 
role of endothelial cells in fibrotic disease comes from in vitro studies or from serum 
markers in human fibrotic diseases. The role of endothelial cells in the commonly used 
BLM mouse model of pulmonary fibrosis has not been extensively characterized. We 
hypothesized that subcutaneously administered BLM would target endothelial cells, 
leading to damage. In vitro studies have shown that BLM induces direct damage to 
cells33 and may cause endothelial cell apoptosis in cultured cells43 . To determine whether 
endothelial cells were damaged in vivo, mice were injected with BLM or PBS for 1 week, 
2 weeks or 4 weeks and endothelial cells were collected from the lung by F ACS cell 
sorting by expression of C031 and C045 (C031 + C045-). mRNA was isolated for gene 
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Figure 11: Subcutaneous BLM injection induces infiltration specific macrophage 
sub-populations. C57Bl/6 mice were injected daily with BLM or saline (PBS) for 2 or 4 
weeks. A single cell suspension was made by digesting lungs in collagenase/dispase for 
1 hour and flow cytometric sorting (F ACS) was used to count alveolar macrophages 
(CD 11 b-CD 11 c+ ), interstitial macro phages (CD 11 b+CD 11 c-) and dendritic cells 
(CD 11 b+CD 11 c+ ). Representative dot plots show cell populations in percentages, taken 
from a sampling of 10,000 cells (A) and cell counts represent a total count from one full 
lung (B). Student's two-tailed, unpaired t-test compared BLM samples to saline injected 
samples at the same time-point. (n=3-4, *p :S 0.05, **p :S 0.01 , ***p::; 0.001) 
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Table 2: Summary of cell populations in FACS sorting0 
CDllb- CDllc+ CDllb+ CDllc- CDllb+ CDllc+ 
PBS 2 weeks 6.78 +/- 1.29 10.47 +/- 2.47 1.84 +I- 0.73 
PBS 4 weeks 4.02 +/- 2.86 5.17 +/- 1.95 0.54 +I- 0.36 
BLM 2 weeks 2.00 +/- 0.27 *** 25.98 +/- 13.82 * 2.89 +/- 1.09 
BLM 4 weeks 0.53 +/- 0.19 * 22.90 +/- 7.85 ** 4.76 +I- 1.24 ** 
0 Data are represented as percentages, (n=3-4, *p::; 0.05, **p::; 0.01 , ***p ::; 0.001) 
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expression analysis of damage markers. Von Willebrand Factor (vWF) has long been 
implicated as a marker for endothelial damage and up-regulated in serum of SSe patients 
93 To better understand the distribution of vWF expression at the protein level in 
endothelial cells, lung tissue was stained by IHC (Fig 12B). Expression of vWF was 
predominantly localized around blood vessels of lungs from PBS mice with minor 
interstitial staining observed in some samples. After two weeks of BLM treatment, vWF 
expression was enhanced around the blood vessels and within the interstitium. As a 
second marker of endothelial injury, MMP12 is increased in skin and serum of SSe and 
correlated with vascular damage and pulmonary fibrosis 169 . MMP12 is most highly 
expressed in macrophages, but was shown to be induced in many different cell types, 
including endothelial cells, during SSc-ILD 169. In isolated endothelial cells from BLM 
injected mice, we observed a marked up-regulation in Mmp12 expression, which reached 
statistical significance at 4 weeks (Figure 12A). These data suggest that endothelial cells 
are damaged in an animal model of chronic lung injury, similar to endothelial damage 
associated with SSe 93 ' 169 . We next questioned what effects damage had on the global 
expression and behavior of endothelial cells . 
Global gene expression patterns in pulmonmy endothelial cells from ELM-injured lungs 
The main features of SSe include inflammation and autoimmunity, vasculopathy 
and fibrosis. Due to cell cross-talk, each of these processes may influence one another 
and exacerbate symptoms. Progressive vasculopathy typically develops years before 
fibrotic disease in SSe, and persists into later stages, possibly contributing to fibrosis 2• 3 . 
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Figure 12: Evidence of endothelial injury by BLM injection in mice. mRNA was 
isolated from FACS sorted pulmonary endothelial cells (CD31 + CD45-) of 1, 2 or 4 week 
BLM or saline injected animals. Gene expression of vascular injury markers vWF and 
Mmpl2 (A) were quantified by qRT-PCR. Data showing fold difference was normalized 
to endothelial cells from normal (saline injected) lungs. Vascular injury was confirmed 
by IHC of vWF (B) in saline, 2wk BLM and 4wk BLM lung sections. Representative 
images are shown at high magnification, with nuclei stained by hematoxylin (200x, scale 
bar = 50flm). Relative expression is quantified by the ~~Ct method and represented as a 
fold change, normalized to endothelial cells from normal (saline injected) lungs at the 
same time-point. Student's two-tailed, unpaired t-test compared endothelial cells from 
BLM lungs to saline injected lungs. (n=4, *p :::; 0.05) 
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We hypothesized that damaged endothelial cells contribute to progressive inflammation 
and fibrosis in the BLM model of pulmonary fibrosis. To determine changes in global 
gene expression, we first used microarray analysis to compare endothelial cells from 
lungs of PBS v BLM injected mice at 28 days (Figure 13). In this experiment, over 
21,000 genes were analyzed with 360 genes increased more than 2 fold and 189 genes 
decreased more than 2 fold. The 25 most highly induced transcripts are listed in Figure 
13. Importantly, osteopontin (anti-apoptotic and pro-fibrotic gene) and MMP12 were 
increased, suggesting vascular damage response, transporters for calcium, peptidase 
inhibitors, among other classes of genes. Many genes were involved in immune function 
such as chemokine/chemokine receptors, complement cascade, and cytokines. 
Activation and expression of adhesion molecules in endothelial cells from ELM-injured 
lungs 
Activation of endothelial cells plays an important role in the recruitment of 
immune cells to sites of tissue injury. Recruitment of immune cells involves a process of 
rolling, binding and extravasation through the vascular wall; this process is mediated by 
adhesion molecules on the vascular surface. Selectins, responsible for loose cellular 
contacts, are up-regulated in vitro and acutely in vivo [14-17] on the endothelium in 
response to BLM. ICAMl and VCAM bind to integrins on immune cells, are responsible 
for firm binding, and have been shown to be up-regulated in endothelial cells in vitro and 
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Figure 13: Microarray analysis reveals role for endothelial cells in inflammation in 
BLM model. A mousel .OST array was run comparing isolated endothelial cells (CD31 + 
CD45-) from lungs of BLM and PBS injected mice. Fold change was computed by 
normalizing to expression in the PBS group. The top 25 up-regulated genes were 
graphed. (n=l) 
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mouse model of fibrosis . To determine when endothelial cells were activated in our 
model, expression of adhesion molecules was quantified in isolated pulmonary 
endothelial cells (CD31+ CD45-) from 1, 2 and 4 week BLM or PBS injected animals 
using qPCR. Surprisingly, there were no observed changes in Icam1 or Yearn and 
changes in expression of the Selectins was relatively late (Figure 14). There was an 
increased trend of E-selectin and P-selectin expression in the second week, with 
variability in expression among samples. At 4 weeks, expression of P-selectin was just 
short of significance in the BLM treated group (p=0.05046). Cd34, a ligand for L-
selectin, also had an increased trend, reaching significance in the fourth week (Figure 
14A). Expression of ICAM1 and VCAM was relatively stable in endothelial cells 
throughout the four weeks of BLM injections, despite previous reports 101' no, 171 . There 
are many molecules that are important in the recruitment of immune cells . Along with 
adhesion molecules, chemokines provide the signals that recruit cells, delivering 
important information on the source of injury. To have a more complete picture of 
immune cell recruitment during the BLM model of pulmonary fibrosis, we aimed to 
quantify changes in chemokine expression. 
Activation and expression of chemokines in endothelial cells from ELM-injured lungs 
Extravasation of leukocytes relies on coordination of signals, including expression 
of chemokines and adhesion molecules on the endothelium 172. Expression of 
chemokines have been noted in serum of patients with SSe, including CCL2, CCh3, 
CCL4 and CXCL8 95 . In a separate study, expression ofCCL2 was correlated with 
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Figure 14: Enodthelial cells from lungs of BLM injected mice express selectins. 
rnRNA was isolated from FACS sorted pulmonary endothelial cells (CD31+ CD45-) 
from 1, 2 or 4 week BLM or saline injected mice. Gene expression was compared in 
adhesion molecules of the selectin family (A) and ligands for the integrin family (B). 
Relative expression is quantified by the ~~Ct method and represented as a fold change, 
normalized to endothelial cells from a normal (saline injected) lung at the same time-
point. Student's two-tailed, unpaired t-test compared endothelial cells from BLM lungs 
to saline injected lungs. (n=4, *p ::; 0.05) 
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pulmonary fibrosis in SSe 97. From our microarray (Figure 13), many of the CCL 
chemokines were highly induced at 4 weeks (Ccl2, Ccl3 , Ccl6, Cc17, Cc19). We aimed to 
confirm the microarray analysis and determine the time-course of chemokine release in 
pulmonary endothelial cells after ELM-injury. To determine this , qPCR was used to 
confirm our microarray findings and to characterize the early response in our system. We 
observed a significant induction of Ccl2, a strong chemotactic factor for macrophages, at 
both 2 weeks and 4 weeks. Other CCL chemokines (Cc13 , Ccl6, Cc17 and Cc19) were all 
elevated at 4 weeks, while CCL6 and CCL9 were significantly increased at 2 weeks 
(Figure 15A). Though chemokine expression is considered redundant, the CCL family is 
an important for monocyte recruitment, while the CXC family is typically important in 
neutrophil recruitment 1 CXCLl and CXCL2 have also been shown to be increased in 
BLM induced lung fibrosis 173 . Though Cxcl2 was elevated between 1 to 4 weeks, and 
significantly increased at 4 weeks in endothelial cells from lungs of BLM treated mice 
(Figure 15B), the fold-change was much lower than that of the CCL chemokine family. 
In addition to roles in leukocyte extravasation, the microarray revealed other 
inflammatory properties of endothelial cells exposed to bleomycin, and these changes 
were investigated further. 
Expression of inflammatory mediators in endothelial cells from ELM-injured lungs 
Among genes that were up-regulated in endothelial cells after 4 weeks of BLM 
treatment (Figure 13) were receptors for C3a and C5a anaphylatoxins. C3a and C5a are 
small pep tides released upon activation of the complement system during early immune 
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Figure 15: Endothelial cells from lungs of BLM injected mice express chemokines 
predominantly in the CCL family. mRNA was isolated from FACS sorted pulmonary 
endothelial cells (CD31 + CD45-) from 1, 2 or 4 week BLM or saline injected mice. 
Gene expression of chemokines in the CCL (A) and CXCL (B) families were compared 
in endothelial cells from PBS and BLM injected animals. Relative expression is 
quantified by the 88Ct method and represented as a fold change, normalized to 
endothelial cells from a normal (saline injected) lung at the same time-point. Student's 
two-tailed, unpaired t-test compared endothelial cells from BLM lungs to saline injected 
lungs. (n=4, *p :S 0.05, **p :S 0.01) 
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activation. Expression of C3aR and C5aR was recently described in endothelial cells 
and shown to synergistically up-regulate chemotactic factors in response to an 
inflammatory stimulus such as IL6 174. We aimed to confirm the changes in 
inflammatory mediators that were observed from the microarray (Figure 13) and expand 
upon the timing of events. Following BLM lung injury, C3aR and C5aR were elevated at 
two weeks, reaching statistical significance at the fourth week (Figure 16A). in vitro 
studies have shown synergistic activation of the anaphylatoxin receptors with IL6 
activation. In our system IL6, was not elevated in endothelial cells (Figure 16B). 
Interestingly, microarray results showed an increase in Oncostatin-M (Osm) and 
Leukemia Inhibitory Factor (Lif), both members of the IL6 family (Figure 13). As a 
confirmation of these results, Osm and Lif were quantified by qPCR and both were 
elevated in the first and second week, reaching statistical significance in the fourth week. 
Together, results showing elevation of adhesion molecules, chemokines, anaphylatoxin 
receptors and cytokines show participation of endothelial cells in inflammation after 
BLMinjury. 
Expression of pro-fibrotic mediators in endothelial cells from ELM-injured lungs 
In vitro, endothelial cells have been shown to secrete pro-fibrotic mediators such 
as TGF~, P AI -1 and CTGF, inducing fibroblast growth, differentiation and synthesis of 
collagen 98-101. Recent evidence has also shown that endothelial cells may become 
fibroblast-like and secrete collagen through endothelial to mesenchymal transition 
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Figure 16: Endothelial cells from lungs of BLM injected mice perpetuate the 
inflammatory response. mRNA was isolated from F ACS sorted pulmonary endothelial 
cells (CD31 + CD45-) from 1, 2 or 4 week BLM or saline injected mice. Gene expression 
of complement receptors (A) and IL-6 family of cytokines (B) were compared in 
endothelial cells from PBS and BLM injected mice. Relative expression is quantified by 
the ~~Ct method and represented as a fold change, normalized to endothelial cells from a 
normal (saline injected) lung at the same time-point. Student's two-tailed, unpaired t-test 
compared endothelial cells from BLM lungs to saline injected lungs. (n=4, *p ~ 0.05, **p 
~ 0.01) 
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(EndoMT), a process similar to epithelial to mesenchymal transition (EMT) 102. To 
detennine the extent to which endothelial cells contribute to the fibrotic process, we 
analyzed gene expression of fibrotic mediators and EndoMT/EMT markers in isolated 
pulmonary endothelial cells from BLM treated mice. Expression of Tgff31 mRNA was 
reduced at 1 week, but there was no difference in expression at · 2 and 4 weeks when 
compared to endothelial cells from PBS injected mice. Gene expression of Pail in 
endothelial cells was significantly increased at 4 weeks in lungs of BLM treated mice. 
Ctgf was elevated in the first week, reaching significance in the fourth week (Figure 
17A). Consistent with previous reports, 52 markers for EndoMT, fibronectin and Fspl, 
were both elevated in endothelial cells after ELM-injury (Figure 17A). Fibronectin was 
elevated early, reaching significance in the second and fourth week, while Fsp-1 was also 
elevated early, showing significance in the fourth week. Interestingly, Osteopontin 
(OPN), a pro-fibrotic and pro-inflammatory molecule was highly induced in the second 
and fourth week following ELM-injury (Figure 17B). Our results show that endothelial 
cells in BLM induced lung injury may have similarities to SSe driven skin and lung 
fibrosis, affecting inflammation (Figures 8,1 0,11) and fibrosis (Figure 9). It remains to 
be determined whether the BLM model in mice recapitulates some of the vascular effects 
ofhuman SSe. 
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Figure 17: Endothelial expression of pro-fibrotic mediators in response to BLM in 
vivo. mRNA isolated from F ACS sorted pulmonary endothelial cells (CD31 + CD45-) of 
1, 2 or 4 week BLM or saline injected animals were used to compare gene expression of 
pro-fibrotic mediators . Expression of A. secreted mediators (Pai-l , Ctgf, Tgfj31), 
EndoMT markers (Fn, Fspl) B. and Osteopontin were quantified by the ~~Ct method 
and represented as a fold change, normalized to endothelial cells from a saline injected 
lung at the same time-point. Student' s two-tailed, unpaired t-test compared endothelial 
cells from BLM lungs to saline injected lungs. (n=4, *p ::S 0.05, **p ::::; 0.01 , ***p ::::; 
0.001). 
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Expression of vascular mediators in endothelial cells from ELM-injured lungs 
Patients with SSe experience symptoms of vasculopathy including Raynaud' s 
phenomenon and digital ulcers . Vascular remodeling in skin has been reported in mice 
after subcutaneous bleomycin injections 162, and in humans, Raynaud' s phenomenon has 
been reported after chemotherapeutic treatment with bleomycin 175 . Many abnormalities 
in the vasculature of SSe patients have been attributed to elevated expression of 
endothelin-1, which is primarily expressed by endothelial cells and is converted to an 
active enzyme by endothelin converting enzyme (ECE 1 ). ET -1 control of vascular tone 
is believed to contribute to fibrosis . Also changed in SSe, is the reduced expression of 
eNOS, which produces the vasodilator nitric oxide (NO) 15 . Expression of Et-1, Ece-1 
and eNos were measured in endothelial cells isolated from the lungs of BLM treated 
mice to determine whether the model recapitulated the vascular effects previously 
shown in SSe vascular disease. Expression of Et-1 and eNos mRNA was unchanged 
throughout the time-course in endothelial cells from lungs of mice exposed to BLM. 
Ece-1 was mildly reduced at 1, 2 and 4 weeks, an effect that was significant at 2 weeks 
(Figure 18A). Loss of vascular integrity has been reported in lungs from ELM-injected 
animals 176 . Additionally, decreased Claudin-5, a tight-junction molecule expressed by 
endothelial cells, has been noted in the BLM model of pulmonary fibrosis 177. Similar 
changes in adhesion molecules involved in maintenance of vascular integrity have been 
noted in patients with SSe, with loss ofVE-Cadherin 15 . To examine whether there was 
evidence for changes in vascular integrity, we measured the expression ofVe-cadherin, 
Cd31 , J arn2 and Claudin 5 in endothelial cells isolated from lungs of mice treated with 
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BLM. Ve-cadherin, Cd31 and Jam2 were mildly decreased at 2 weeks, though only 
Cd31 was significant (Figure 18). Changes in expression of adhesion molecules that 
maintain the vascular wall were transient. 
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Figure 18: Endothelial expression of vascular mediators in response to BLM in vivo. 
mRNA was isolated from FACS sorted pulmonary endothelial cells (CD31 + CD45-) 
from 1, 2 or 4 week BLM or saline injected mice. Gene expression ofvascular mediators 
(A) and adhesion molecules involved in vascular integrity (B) were compared in 
endothelial cells from PBS and BLM injected mice. Relative expression is quantified by 
the ~~Ct method and represented as a fold change, normalized to endothelial cells from a 
normal (saline injected) lung at the same time-point. Student' s two-tailed, unpaired t-test 
compared endothelial cells from BLM lungs to saline injected lungs . (n=4, *p :S 0.05, **p 
:::: 0.01) 
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DISCUSSION 
While skin fibrosis in SSe is generally believed to be caused by injury to the 
endothelium, little is known about the involvement of endothelial cells in SSc-ILD and 
IPF. Recent reports have suggested that endothelial cells may be damaged by anti-
endothelial antibodies in SSc-ILD and in subsets of IPF patients 178. In this study our 
goal was to characterize the response of pulmonary endothelial cells to subcutaneous 
administration of BLM. Endothelial cells were injured in response to BLM, as evidenced 
by expression of vascular injury markers MMP12 and vWF. We reported increased 
number of interstitial macrophages in the lung tissue following two weeks of BLM 
injury, which correlated with increases in endothelial expression of selectins and 
chemokines. Endothelial cells further contributed to inflammation (complement 
receptors, IL6 family cytokines) and fibrotic processes, by up-regulated expression of 
pro-fibrotic mediators and endoMT markers. 
For the purpose of our study, we chose a chronic lung injury model, in which the 
lung was repeatedly damaged by small, daily doses of bleomycin. In contrast to acute 
models of lung injury, chronic injury tends to produce overlapping phases of injury, 
inflammation and repair 1. Our results in endothelial cells are consistent with this model 
of lung injury and repair. The earliest responses were elevated endothelial injury markers 
within the first week that were sustained into later phases. Within the later phase 
overexpression of inflammatory response genes (selectins, chemokines, and cytokines) 
and fibrotic genes (Ctgf, Osm) into the fourth weeks exemplifies the overlapping 
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responses. For the study of certain types of human ILD, an acute model of lung injury 
may be accurate. However, SSe fibrosis (skin and lung) and IPF are believed to develop 
over many years with repeated bouts of injury, offering credence to the use of chronic 
injury models for the study of these diseases. 
Currently, little is known about the in vivo role of endothelial cells during 
bleomycin lung injury. Literature reports have cited changes in adhesion molecules 170' 
179
' 
180
, cytokines 170' 179' 181 , vascular mediators 182 and pro-fibrotic molecules 98-100 after 
in vitro treatment of endothelial cells with bleomycin, but many of these mediators are 
not verified in vivo. Furthermore, presence of cytokines and chemokines in bronchiolar 
lavage fluid and serum has been reported in patients or in animals treated with 
bleomycin, but cell origin of these mediators is either unknown or is assumed based on 
in vitro data. In our study, we used a methodology that can accurately detect the 
regulation of genes in an isolated cell population. Though confirmation of endothelial 
localization in human lung biopsies will be beneficial for the markers described, the cell 
sorting method would not be possible in human samples. Human samples often present 
difficulties in obtaining proper controls, and are often not suitable for cell isolation 
which must be done on fresh tissues. Both of these problems are overcome using animal 
models of disease. 
Endothelial cell apoptosis has been shown in lungs injured by BLM 42 , however, 
the role of apoptosis has been debated in scleroderma 15 . In patients with SSe, 
endothelial injury was shown by increased circulating vWF 92, and increased 
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Angiotensin Converting Enzyme (ACE) was used as an endothelial injury marker in 
serum or BAL of mice exposed to BLM 182. vWF initiates thrombus formation in 
response to denudation of the vascular wall23 , its expression is thus induced upon injury 
to endothelial cells and is likely a protective mechanism183 . In our system, we observed 
an early increase in vWF expression in endothelial cells, suggesting injury to the 
endothelium. As further evidence of vascular injury, we showed an early up-regulation 
of Mmp 12 in endothelial cells. In a recent publication by Manetti, et a/. 169, increased 
MMP12 in the serum of patients with scleroderma correlated with severity of pulmonary 
fibrosis and with vascular injury. We have shown the first report of Mmp12 up-
regulation in endothelial cells from mice treated with BLM, further confirming 
endothelial injury in this model. 
As a measure of endothelial cell activation and interaction with the immune 
system, we measured the expression of adhesion molecules and chemokines in 
endothelial cells. Over-expression of selectins (E-selectin, P-selectin, and Cd34) and 
CC chemokines (Cxcll, Cxcl2, Ccl2, Ccl3, Ccl6, Ccl7, and Ccl9) suggest that 
endothelial cells contribute to homing of immune cells to sites of injury. Though others 
have reported an increase in E-selectin and P-selectin after BLM injury 179, 180, 184, 185 , 
induction of selectins has typically been shown at an early time-point. Serrano-Mollar, 
et al. 185 showed P-selectin induction after 1 hour, which returned to basal levels after 3 
hours. In our study, we show a late and prolonged induction of P-selectin, E-selectin 
and CD34. Further evidence of endothelial activation and immune system involvement 
is in the induction of the IL-6 family of cytokines, Lif and Osm. Interestingly, 
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Oncostatin M (Osm), was shown to induce prolonged activation of P-selectin in 
endothelial cells in vitro 186 and is elevated early (1 week) in our system. In SSe, Osm 
has been reportedly increased in serum and BAL from patients with scleroderma related 
lung disease 187. Together, the prolonged expression of the selectin family of adhesion 
molecules with CC chemokines, which typically recruit monocytes 166, suggests an 
important role of endothelial cells in monocyte recruitment after BLM. 
Up-regulation of complement receptors (Fig 4C) further suggests that endothelial 
cells are activated after BLM treatment in vivo. Endothelial cells have been shown to 
constitutively express low levels of Complement Sa receptor (C5aR), which is induced 
further after treatment of endothelial cells in vitro with pro-inflammatory cytokines, 
including LPS, IL6 or IFN-y 174. Activation of complement has been noted in many 
autoimmune and inflammatory diseases 188 and depletion of complement has been shown 
to attenuate ELM-induced pulmonary fibrosis in mice189 . Evidence from Laudes, et al. 
174 suggests that activation of C5aR can act synergistically with pro-inflammatory 
cytokines in endothelial cells. Co-stimulation of C5a and IL6 led to an enhanced 
production of MCP-1/CCL2 and MIP-2/CXCL2 in endothelial cells in vitro . From our 
work, C5aR and C3aR were induced within the second and fourth weeks, suggesting 
that up-regulation and engagement of C5aR and C3aR may enhance and sustain the 
inflammatory response. 
In SSe, endothelial cells are believed to contribute to the development of skin 
fibrosis, but little is known about the role of endothelial cells in pulmonary fibrosis. In 
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vitro studies have shown that endothelial cells secrete many pro-fibrotic mediators, 
among these, TGFP 98-100, CTGF 98, and PAI-1 101 are up-regulated after stimulation of 
endothelial cells with BLM in vitro. From our studies, Ctgfwas elevated in endothelial 
cells between the first and fourth weeks after BLM stimulation, and was significant in 
the fourth week. Pai-l, a target of TGFP that is associated with tissue fibrosis and 
wound healing 190-192 , was also significantly increased in the fourth week. P AI -1 is the 
main inhibitor of fibrinolysis and is speculated to play an additional role in tissue 
fibrosis through inhibition of MMP activity and modulation of the inflammatory 
response 191. These data suggest that endothelial cells may contribute to the proliferation 
and activation of near-by fibroblasts in vivo . 
We found that Osteopontin was significantly elevated within one week in 
pulmonary endothelial cells exposed to bleomycin. Osteopontin is a pro-fibrotic 
cytokine with many functions in fibrosis and inflammation. It is up-regulated in IPF 193 
and SSe-dermal fibrosis 194 in fibroblasts, macrophages and epithelial cells 193• 194. 
. ll . . k ' 194 d 1 fib . 195 . . d . h Osteopontm nu rmce were resistant to s m an ung I rosis m m1ce treate w1t 
BLM. Reduced fibrosis in OPN_,_ mice has been attributed to effects of OPN on 
fibroblasts or macrophages. Macrophages secrete large amounts of TGFP during 
fibrosis , an effect that is greatly attenuated in OPN deficient macrophages 194. 
. d . . d lifi . . fib bl 193 194 Th h Furthermore, OPN m uces migratiOn an pro eration m ro asts ' . oug a 
pro-fibrotic role of OPN in endothelial cells has not been described, the secretion of 
OPN may have significant effect on surrounding cell types . 
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As an additional mechanism of endothelial cell contributions to fibrosis, 
endothelial cells may take on a fibroblast-like phenotype through Endothelial to 
mesenchymal transition (EndoMT), and contribute to the secretion and deposition of 
collagen in tissue 52. To test this, we measured the expression of Fibronectin (Fn) and 
Fibroblast Specific Protien-1 (Fsp-1), both markers for EndoMT. Fibronectin (Fn) is 
also a component of the extracellular matrix and is secreted at areas of injury. It has 
been shown that increased Fn expression precedes the development of pulmonary 
fibrosis in rats treated with BLM 196. In our system, fibronectin was elevated in 
endothelial cells early, and was significantly increased by the second week (Figure 17). 
Interestingly, fibronectin has a well-known function in wound healing and fibrosis and 
may contribute to fibroblast adhesion, contraction and motility 197. This suggests that a 
local change in the pro-fibrotic milieu of endothelial cells after injury contributes 
directly to the fibrotic process, possibly accounting for a sustained and self-perpetuating 
fibrotic response. 
In addition to skin and organ fibrosis, a major characteristic of scleroderma is 
vascular dysfunction 15• 198• 199. Overexpression of endothelin-1 and down regulation of 
eNos in endothelial cells has been suggested to trigger abnormal vasoconstriction, 
contributing to Raynaud's phenomenon and pulmonary hypertension in SSe patients. 
Park, et a!. 200 reported an increase in total levels of endothelin-1, localized to airway 
epithelium and inflammatory cells but not endothelial cells of BLM treated mice. 
Endothelin converting enzyme-1 (Ece-1) was also reportedly increased in the airway 
epithelium, type II pneumocytes and endothelium but not in immune cells. In our study, 
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we found a slight decrease in Ece-1, and no changes in expression of Et-1 or eNos in 
endothelial cells from BLM lungs (Figure 18B). In addition to changes in vascular tone, 
vasculopathy in SSe includes loss of vascular integrity, as evidenced by the loss of VE-
cadherin connections and gaps between endothelial cells 15 ' 155 . Contrary to these 
changes in the vasculature of humans with SSe, we found minimal changes in adhesion 
molecules known to maintain vascular integrity, including Claudin 5, Ve-cadherin, 
Pecam/CD31 and J am2 (Figure 18A). We concluded that there was little evidence for 
changes in the integrity of the vascular barrier or in vascular tone. 
BLM has been shown through in vitro studies to induce damage to many 
different cell types including endothelial cells, epithelial cells and macrophages43, 46 , 62. 
It not surprising that BLM may damage many different cell types as it can cause direct 
damage to many cell components; including cell membranes and lipids, proteins, DNA 
and RNA, but the main mechanism of action is believed to be through double stranded 
and single stranded breaks of DNA33 . Upon damage, endothelial cells respond by 
regulating inflammation23 . Endothelial cells may also be damaged and activated by 
alternative mechanisms from other injured cell types, such as macrophages and 
epithelial cells, as there is considerable cell cross-talk within the lung (Figure 19). 
While it is unlikely that endothelial cells are damaged while other cell types are spared, 
there is ample evidence to suggest that there is a direct mechanism of endothelial 
damage by BLM. 
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In conclusion, these results suggest that endothelial cells contribute to sustained 
injury responses during BLM induced fibrosis through multiple mechanisms. We have 
shown contribution of endothelial cells to inflammatory and fibrotic processes, 
continuing into late stage disease and potentially perpetuating injury and repair. Up-
regulation of genes involved in vascular iiljury, activation, inflammation and fibrosis 
suggests that cross-talk of endothelial cells with immune cells and fibroblasts is 
important in tissue injury and fibrosis . 
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Figure 19: Working Model: Endothelial Interactions in Pulmonary Fibrosis. 
Previously described cellular interactions during fibrosis have classically involved 
macrophages/innate immunity, fibroblasts and epithelial cells. In our model of 
subcutaneous BLM-induced lung injury, we have shown that endothelial cells are injured 
and respond in ways that promote fibrosis. Upon injury, endothelial cells exhibit 
evidence of pro-inflammatory responses, and interaction and recruitment of 
macrophages. In addition to immune effects, endothelial cells likely contribute directly 
to fibrosis, through fibroblast activation and induction of EndoMT. In conclusion, 
endothelial cells represent an additional target of injury that contributes to complex 
cellular interactions during the development of fibrosis. 
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FUTURE DIRECTIONS 
One of the major goals of this research was to determine what role endothelial 
cells play in the BLM model of fibrosis . Part of this aim, was to--. determine how similar 
this model is to SSc-ILD. One of the major pathological features of SSe is vasculopathy 
which is believed initiate or exacerbate the development of fibrosis 15 . Of the mediators 
that we observed, there were only transient responses in genes that control vascular 
integrity and little evidence for changes in vascular tone in the BLM model (Figure 18). 
It would be interesting to determine through functional assays how closely the BLM 
model recapitulates what is known about vascular disease in SSe, including vasospasm, 
proliferative vasculopathy and blood vessel occlusion. Yamamoto has shown evidence of 
proliferative vascular disease in the skin of subcutaneously injected animals 162. It would 
be interesting to verify this result, to determine the extent of vascular disease in the skin 
and determine whether this result can be extended to other organs. It is possible that 
though vascular disease may be present in the skin of patients with SSe and in the skin of 
animals subjected to subcutaneous BLM instillation, that organ specific differences may 
exist. 
Outside of idiopathic pulmonary fibrosis and scleroderma interstitial lung disease, 
there are many other causes for pulmonary fibrosis. Many cases of pulmonary fibrosis 
are due to chronic injury (environmental exposures, chemical exposures, connective 
tissue disorders, such as SSe) while others are caused by an acute lung injury (ALI) (local 
or systemic inflammation, exposure to radiation, etc) 23 . It is worth examining whether 
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the acute lung injury model displays similar pathological changes in endothelial cells to 
what we reported during chronic lung injury. This would suggest that endothelial injury 
and activation is a conserved process, regardless of the initial injury. 
One aspect of BLM induced pulmonary fibrosis that is unique to the subcutaneous 
instillation route, is that fibrosis tends to be perivascular or sub-pleural, similar to human 
fibrotic lung disease 40. Though increased pro-fibrotic mediators such as CTGF and PAI-
l have been noted in many cell types during fibrosis, including fibroblasts themselves, 
the localization of these mediators may be important in determining the site of fibrosis . 
Endothelial localization of pro-fibrotic mediators may be significant due to their 
proximity to other cell types, including pericytes and smooth muscle cells, which have 
potential to differentiate into myofibroblasts 51' 80' 201 . In the future, it will be important to 
determine whether endothelial localization of pro-fibrotic mediators contributes to 
myofibroblast activation and perivascular fibrosis . 
Much effort has gone in to determining the primary cell target of BLM. Cell 
types of interest have included endothelial cells, epithelial cells or macrophages 43 ' 46, 51 ' 
62
. While BLM has been shown to damage many different cell types, it is likely that the 
instillation method may determine the initial hit. An avenue that has not been explored is 
the possibility that cells within the blood respond to intravenous doses of BLM. Serum 
cytokines are increased in the blood202 and it has been suggested that weight loss in mice 
exposed to BLM is a cachexic response driven by systemic inflammation163 . Perhaps 
endothelial injury is mediated in part by this response, which preferentially causes injury 
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to the lung due to the extensive network of capillaries that are easily damaged. There is 
evidence for this in the fact that many causes of acute lung injury are indirect, including 
sepsis or SIRS 23 . This aspect of endothelial damage in the BLM animal model of 
fibrosis remains to be explored. 
One criticism of the BLM model of pulmonary fibrosis is that fibrosis subsides a 
few months after cessation of BLM treatment in animals. Though it is difficult to assess 
fibrosis over time in humans, it is believed that fibrotic lung disease in humans does not 
improve over time 203 . This may be the result of the models that we use to study fibrosis. 
When a damaging stimulus is removed from the mouse they improve. The situation in 
humans is different, agents of damage are unknown in IPF and SSc-ILD, and cannot be 
removed. Patients are typically treated with immunosuppressive therapy, the use and 
efficacy of which is debated and may depend on the stage of disease. Early, 
predominantly inflammatory disease may benefit from immunosuppression, while late-
stage fibrosis may be unresponsive 2. From our studies, there were multiple phases of 
endothelial activation that were sustained in to late-stage. To determine therapeutic 
potential of any given target, it is essential to identify the stage of disease within the 
patient. From our studies, the prolonged and sustained activation of endothelial cells 
during pulmonary fibrosis makes this cell type a potential target for future therapies. 
94 
CHAPTER 4: Flil is down-regulated in macrophages in response to inflammation 
and injury 
PURPOSE 
Our lab has focused extensively on the transcription factor Flil and its 
involvement in skin fibrosis in patients with scleroderma Previous work from Kubo, et 
al. has shown Flil down-regulation in endothelial cells and in dermal fibroblasts from 
patients with scleroderma 149. Expression of Flil is negatively correlated with collagen 
expression in fibroblasts 149. It was later shown that the Flil transcription factor is a 
negative regulator of fibrosis and binds directly to the promoters of Coll a2 149• 155 and 
CTGF 204 to inhibit their transcription. The pro-fibrotic role of Flil was shown in a 
transgenic mouse model in which one of the protein interaction domains (~CT A) was 
removed, and deposition of collagen was increased in the skin 154. In endothelial cells, 
Flil was shown to contribute to maintenance ofvascular integrity 155 , further supporting 
the importance of this transcription factor in SSe. In this study, a mouse with a 
conditional knockout ofFlil in endothelial cells developed vasculopathy that was akin to 
vascular changes in human SSe 155 . Currently, evidence exists for the role ofFlil in skin 
149
• 
154 and heart fibrosis 205 , but the role of Flil in pulmonary fibrosis, the leading cause 
of mortality in SSe, is unknown. We hypothesized that if down-regulation of Flil was 
a universal process during fibrosis (similar to SSe dermal fibrosis), then Flil 
expression would be decreased following experimental pulmonary fibrosis. To test 
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this hypothesis, we used the subcutaneous injection model ofBLM which closely mimics 
SSe, with the development of skin and lung fibrosis in mice 37. 
AIM3: Determine the mechanism of Flil regulation during pulmonary fibrosis. We 
aimed to determine A. Whether Flil is down-regulated during pulmonary fibrosis, 
mimicking what is seen in human dermal fibrosis. B. Determine in what cell type(s) Flil 
is down-regulated during pulmonary fibrosis, and C. determine the mechanism of 
regulation. Using a combination ofwestem blot, IHC and cell sorting, we characterized 
the expression of Flil at the basal level in various cells of the lung. Upon injection of 
BLM for 28d, Flil expression was decreased. To determine the cell type in which Flil 
was down-regulated during BLM induced fibrosis, mice were injected with BLM or PBS 
and various cell populations were isolated by F ACS sorting (endothelial cells, 
parenchymal cells, immune cells, interstitial macrophages, alveolar macrophages, 
dendritic cells) with subsequent qPCR analysis of Flil levels. The regulation of Fli 1 by 
inflammatory signals in macrophages was further characterized by stimulation with TLR 
ligands. 
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RESULTS 
Expression of Flil in cell types of the lung 
Within a normal lung there are nnmune cells (predominantly resident 
macrophages), endothelial cells, epithelial cells (type I and type II pneumocytes) and 
mesenchymal cells (fibroblasts, smooth muscle cells, pericytes) 23 . Though Fli1 is known 
to be highly expressed in immune cells and endothelial cells 144, relative protein 
expression has not been directly compared in these cell types. To better determine the 
potential cell types expressing Fli1 in the lung and relative expression levels, we analyzed 
protein expression levels of Fli1 in multiple cell types by western blot. We hypothesized 
that at basal conditions, expression of Fli1 is highest in immune cells and endothelial 
cells, with low expression in fibroblasts . To address this, we used western blot analysis 
to compare protein expression of Fli 1 in total cell lysate and within the 
nuclear/cytoplasmic fraction of different cell types. In total cell lysates, expression of 
Fli1 was compared in endothelial cells (HMVECs, primary isolation), fibroblasts (human 
dermal fibroblasts, primary isolation), epithelial cells (mouse mammary gland 
transformed cell line, CRL-1636) and smooth muscle cells (aortic, primary isolation) 
(Figure 20A). Within these samples, Fli1 protein was highly expressed in endothelial 
cells and undetectable in totallysates from fibroblasts, epithelial cells and smooth muscle 
cells. Previous reports from our lab have shown that Fli1 is expressed in fibroblasts and 
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Figure 20: Flil is highly expressed in hematopoetic and endothelial cells and is 
predominantly nuclear. A. Endothelial (HMVECs) primary cell line was obtained from 
human foreskins. Human dermal fibroblast cells are a primary cell line outgrown from a 
human forearm skin biopsy. Two cell lysates were a generous gift from the lab of Dr. 
Matthew Layne: Lysates from a mouse mammary epithelial cell line (CRL-1636) and 
smooth muscle cells from a primary isolation from a mouse aorta. 30ug of total lysate 
were loaded on a 10% acrylamide gel, transferred to a nitrocellulose membrane and 
immunoblotted with mouse anti-human Flil (BD Pharmingen). Membranes were 
stripped and re-probed for ~-actin expression. B. Lysates were obtained from a 
nuclear/cytoplasmic extraction of mouse bone marrow derived macrophages (BMDMs) 
or human dermal fibroblasts and probed for expression of Fli 1, showing nuclear 
localization of Fli 1. 
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that it is predominantly nuclear 149. Fli1 protein was enriched by nuclear/cytoplasmic 
extraction in fibroblasts and expression was compared to nuclear lysate from 
macrophages (Figure 20B). Nuclear protein expression of Fli1 in macrophages (lane 1) 
was high and detectable with a short exposure, while nuclear Fli1 expression in 
fibroblasts (lane 2) was detectable only by a long exposure. Cytoplasmic extracts had 
undetectable levels ofFli1 protein in both macrophages and fibroblasts (lanes 3, 4). We 
have concluded that Fli 1 is a nuclear protein with high expression in endothelial cells and 
macrophages, and lower expression in fibroblasts. We next wanted to determine the 
localization ofFli1 within tissue of the lung. 
Localization and expression of Flil in mouse lungs 
Fli1 is known to be expressed highly in hematopoetic cells and endothelial cells 
144 Additional work in our lab has also shown that Fli1 is expressed at low levels in 
fibroblasts at a basal level (Figure 20 and 149) . In the skin, Fli1 was found as a nuclear 
stain around blood vessels due to its high expression in endothelial cells, with additional 
staining localized in fibroblasts of the dermal layer. Within fibrotic skin from 
Scleroderma patients, Fli1 protein expression was down-regulated in both of these cell 
types 149 . In order to determine the role of Flil in pulmonary fibrosis , we first 
characterized the expression ofFli1 within the lungs at a basal level. It was hypothesized 
that Flil would have a similar expression pattern within the lung to what has been shown 
in dermal biopsies, and that stain would be primarily localized in endothelial cells and 
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fibroblasts. To determine this, we used IHC to determine the cell specific expression of 
Fli1 protein at basal levels (Figure 21). Lungs sections from paraffin embedded tissue of 
a normal (untreated) mouse were used to show localization. Protein staining was 
determined to be specific for Fli1 due to the absence of DAB stain in an isotype control 
stained slide (Figure 21). In this control, the primary antibody against Flil was replaced 
with mouse IgG2b and a section from the same tissue was used. Consistent with our 
hypothesis, and with what has been described from human skin sections, Fli1 staining 
was localized predominantly as a nuclear stain around blood vessels. Additional staining 
was present within cells of the interstitium, and was also nuclear. We postulated that 
expression of Fli1 may change during a pathological state, such as during inflammation 
and fibrosis . 
Down-regulation of Flil in lungs of mice exposed to BLM 
Our lab has shown that Fli1 expression is down-regulated during fibrosis in 
dermal biopsies from patients with Scleroderma when compared to normal donor 
biopsies. Down-regulation of Fli1 was found to play a pathological role in the 
development of fibrosis 149' 154 and vasculopathy 155 . Though skin disease causes severe 
morbidity in Systemic Sclerosis, pathologies of the lung are currently the most common 
cause of death in these patients 6. This led us to question the role ofFli1 as a regulator of 
tissue fibrosis in the lung. We predicted that Fli1 expression would be down-regulated 
during pulmonary fibrosis , similar to what is known regarding Flil in SSe-mediated 
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Figure 21: Flil is expressed around blood vessels and in interstitial cells of the lung. 
The left lung of a C57Bl/6 mouse was fixed by tracheal perfusion and embedded in 
paraffin. A 5!lm section was used for to determine localization of Fli 1 (A) (isotype 
control (B)) by lliC. Figures are representative images. 
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dermal fibrosis 149. To address this question, we used the chemotherapeutic agent 
bleomycin, the most common agent to induce pulmonary fibrosis, in an animal model. 
Bleomycin or saline (PBS) were administered to C57BL/6 mice by daily subcutaneous 
injection. Injection by this mode induces a scleroderma-like skin fibrosis and pulmonary 
fibrosis in bleomycin treated animals 36. Lungs were collected and paraffm embedded for 
analysis of tissue inflammation (Figure 8) and fibrosis (Figure 9A-F). A small piece of 
lung was used to asses m.RNA expression of collagen (Figure 9G) and Flit (Figure 22). 
Flil m.RNA expression was significantly down-regulated in lungs of BLM treated mice 
compared to PBS treated. We next aimed to determine whether reduced Flil expression 
in a mouse model of pulmonary fibrosis had a cell-specific pattern and whether this 
expression pattern was similar to the reduced Flil expression during dermal fibrosis, 
focusing our study on endothelial cells, fibroblasts and macrophages. 
Expression of Flil in lung cell populations and regulation after irifury 
Dysregulation of Flil has been implicated in autoimmune diseases; in endothelial cells 
and fibroblasts in Scleroderma 149 and in immune cells in Systemic Lupus Erythematosus 
(SLE) 148' 206. In SSe, Flil down-regulation is implicated in fibrosis 154 and vasculopathy 
155
. In SLE, overexpression of Flil has been reported in peripheral blood lymphocytes 
and within splenic lymphocytes of lupus prone mice when compared to normal controls 
148
, 
206
. Due to the known dysregulation of Flil in these cell types during autoimmune 
disease, we hypothesized that Fli 1 would be down-regulated within endothelial cells, 
fibroblasts within the parenchymal population, and within the immune cell population of 
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Fli1 
Figure 22: Flil gene expression is reduced in mice after BLM lung injury. C57BL/6 
mice were injected with BLM or saline (PBS) control by subcutaneous route for 28d and 
sacrificed 24h after the final injection. mRNA was extracted from total lung tissue and 
reverse transcribed for quantitative PCR. Analysis used the ~~Ct method and data was 
normalized a saline control. A two-tailed, unpaired Student's t-test compared Flil 
expression in BLM samples to PBS control samples (n=4-5). 
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fibrotic lungs. To address this question, we used the BLM model of pulmonary fibrosis 
and fractionated the lung into different populations of cells using FACS cell sorting. To 
isolate endothelial cells, immune cells and parenchymal cells, the markers CD31 and 
CD45 were used. After cell sorting, RNA was isolated and used to compare Flillevels in 
each cell population in lungs from PBS and BLM injected animals. We first compared 
Flil expression at a basal level (PBS injected mice) in immune cells (CD31- CD45+) 
endothelial cells (CD31 + CD45-) and non-endothelial parenchymal cells (CD31- CD45-) 
(Figure 23). It was determined that the highest level of expression was in the endothelial 
cell population, which is consistent with previous reports 207 . 
The immune cell population includes lymphocytes, granulocytes and 
macrophages, and expressed Flil at nearly twice the level of parenchymal cells (epithelial 
cells, fibroblasts, pericytes and smooth muscle cells). While parenchymal cells typically 
include endothelial cells, they are excluded from this sort. To determine whether Flil 
expression was decreased within each population of cells after BLM treatment, we 
compared Flil expression in cells from PBS treated animals and compared to cells from 
BLM treated. Contrary to our hypothesis, there was no change in endothelial cell 
expression ofFlil after BLM treatment and no change in immune cell expression of Flil. 
Surprisingly, Flil was decreased in the parenchymal cell population only, but not within 
the immune cell or endothelial cell populations. The parenchymal population includes 
fibroblasts among other cell types . Because the immune cell population represents a 
heterogeneous population of cells, we next observed the regulation of Fli 1 in 
macrophages, an important cell type in the pathogenesis of fibrosis 3' 13 . 
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Figure 23: Flil is most highly expressed in endothelial cells and down-regulated in 
parenchymal cells after BLM injury. C57Bl/6 mice were injected daily with BLM or 
saline (PBS) for 4 weeks. A single cell suspension was made by digesting lungs in 
collagenase/dispase for 1 hour, stained with CD31 and CD45, and flow cytometric 
sorting (F ACS) was used to sort endothelial cells (CD31 + CD45-), immune cells (CD31-
CD45+) and non-endothelial parenchymal cells (CD31- CD45-). mRNA was extracted 
and used to quantify expression of Fli 1 by qPCR. eDNA from the PBS group was used 
to compare basal expression of Fli 1 in each cell population. Data is represented as 
relative expression and normalized eDNA from total tissue (A). Expression of Fli 1 in 
each cell population was compared between PBS and BLM treated groups. Data is 
presented as relative expression, normalized to cells from the PBS control group (B). 
Analysis used the ~~Ct method and statistical analysis used Student's two-tailed 
unpaired t-test. (n=3-4, *p 2: 0.05) 
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Expression of Flil in macrophage subpopulations of the lung and regulation after injury 
Macrophages have long been held to play a pathological role in the development 
of pulmonary fibrosis 58. In our studies from the previous chapter, we have shown that 
the lung contains distinct populations of macrophages within the lung, and that the total 
number of interstitial macrophages (COllb+ COlle-) is increased after BLM injury in 
the lungs (Figure 11, Table 2). Because immune cells express nearly twice the levels of 
Flil as mesenchymal cells (Figure 23), it is surprising that Flil is decreased in total lung 
tissue (Figure 22), as we would expect to see a relative increase in Flil expression upon 
BLM injury due to infiltration of macrophages. In the previous figure (Figure 23), Flil 
was not decreased in immune cells, which represents a heterogeneous population of cells 
and includes lymphocytes, granulocytes, mast cells, macrophages, etc. We questioned 
whether we would observe a decrease in Flil in a cell population enriched for 
macrophages. It was hypothesized that Flil expression would be reduced within the 
interstitial macrophages (COllb+ COlle-) after BLM treatment in the lungs. To 
determine this, we used F ACS cell sorting to isolate macrophage sub-populations in the 
lungs and compared Flil expression at the basal level and after BLM injury. At the basal 
level, expression of Flil was compared to the total population of immune cells (C031-
C045+) from the previous experiment (Figure 23). Expression of Flil is roughly equal 
within interstitial macrophages (COllb+ COlle-) and dendritic cells (COllb+ 
COlle+), where it is roughly 1.5x as high as in immune cells (C031- C045+). 
Expression was much lower within alveolar macrophages (COllb- COlle+) (Figure 
24A). Interestingly, interstitial macrophages, which are increased in number after BLM 
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Figure 24: Flil is down-regulated in interstitial macrophages following BLM injury. 
C57Bl/6 mice were injected daily with BLM or saline (PBS) for 4 weeks. Lungs were 
perfused through the right ventricle and a single cell suspension was made by digesting 
lungs in collagenase/dispase for 1 hour, stained with CD 11 b and CD 11 c, and flow 
cytometric sorting (F ACS) was used to sort alveolar macro phages (CD 11 b-CD 11 c+ ), 
interstitial macrophages (CD11b+CD11c-) and dendritic cells (CD11b+CD11c+). 
mRNA was extracted and used to quantify expression ofFlil by qPCR. eDNA from the 
PBS group was used to compare basal expression ofFli1 in each cell population. Data is 
represented as relative expression and normalized to eDNA from immune cells (CD31-
CD45+) (A). Expression ofFlil in each cell population was compared between PBS and 
BLM treated groups. Data is presented as relative expression and normalized to cells 
from the PBS control group (B). Analysis used the ~~Ct method and statistical analysis 
used Student's two-tailed unpaired t-test. (n = 3-4, *p 2: 0.05) 
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injury, show a relative decrease in Flil mRNA level in lungs of BLM injected mice 
compared to lungs from the PBS group (Figure 24B). Next, we chose an in vitro system 
to determine the process of Flil down-regulation in macrophages using a mouse 
immortalized cell line and a primary cell line from mouse tissue. 
Regulation of Flil by TLR stimulation in cultured macro phages 
Accumulation of macrophages has been noted in SSe, ILD and during BLM 
induced lung injury. Bleomycin may activate lung macrophages through direct and 
indirect mechanisms, including direct engagement of TLR2 or TLR4 by bleomycin 64 or 
indirect TLR activation from release of endogenous ligands 208. Further immune 
activation may be a result of cytokine release 64. From our studies on macrophages, Flil 
transcript was decreased in isolated interstitial macrophages (CDllb+CDllc-) from 
BLM injected animals (Figure 24B). We hypothesized that Flil was regulated by 
inflammatory signals during BLM induced lung injury and fibrosis. To answer this 
question, we used an in vitro system to study the regulation ofFlil after an inflammatory 
stimulus. We used a primary isolation of macrophages from mouse bone marrow (bone 
marrow derived macrophages/BMDMs) and treated them with the following panel of 
TLR agonists; Pam3Cys (TLR 2), LPS (TLR 4), R837 (TLR7) and CpGb (TLR9). We 
observed a significant down-regulation of Flil by stimulation with all TLRs (with the 
exception of R837 which worked in 2 out of 3 experiments). The most potent effect on 
Flillevels was by LPS, a TLR4 agonist (Figure 25A). To determine how sensitive Flil 
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Figure 25: Flil is down-regulated in BMDMs following TLR activation. Bone 
marrow derived macrophages (BMDMs) were isolated from mouse bone marrow and 
differentiated over six days. Cells were cultured in the presence of TLR agonists for 6 
hours: TLR2 Agonist Pam3Cys (l!J.g/mL), TLR4 agonist LPS (l!J.g/mL), TLR9 agonist 
CpGb (1!J.g/mL) and TLR7 agonist R837 (5!J.g/mL). mRNA was extracted from cells and 
reverse transcribed for qPCR. Analysis used the t1t1Ct method and data was normalized 
to a control (media) sample for each experiment. A Student's unpaired two-tailed t-test 
compared control (media) to TLR stimulated macrophages (n=3) (A). In a separate 
experiment, BMDMs (B) or RAW cells (C) were cultured in the presence of different 
concentrations ofLPS for 6 hours (n=1). (**p 2:0.01, ***p 2: 0.001) 
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was to LPS stimulation in macrophages, we used a dosage response at 6 hours in both 
BMDMs and a transformed monocyte/macrophage cell lines (RAW cells). In BMDMs, 
stimulation by LPS drove down the expression of Flil mRNA at all concentrations 
chosen, and cells were sensitive to as little as 1 Ong/mL of LPS (Figure 25B). In RAW 
cells, we observed a dosage dependent down-regulation of Flil transcript, which were 
sensitive to as little as 1 OOpg/mL of LPS (Figure 25C). Next, we wanted to determine 
how rapid down-regulation ofFlil was upon stimulation ofmacrophages by LPS. 
Time-course of cytokine expression and Flil down-regulation by LPS in cultured 
macro phages 
Regulation of Flil has previously been reported at the transcriptional level by 
certain inflammatory mediators , including LPS and IFNy 209, but the kinetics of this 
response was not reported. To address this question, we stimulated BMDMs and RAW 
cells with 1 ug/mL ofLPS for 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1, 2, 4, 6 and 24 
hours . We observed the expression of the cytokines TNFa and IL-l , as well as 
expression ofFlil over the time-course. In BMDMs, TNFa and IL-l were induced very 
early, in only 15 minutes. TNFa transcript reached maximal levels at 45 minutes and 
began to decline around 2-6 hours. IL-l was increased over 300 fold by 45 minutes, 
reached maximal levels at 6h and did not decline by 24h (Figure 26A). The mRNA level 
of Flil began to decrease by 2h, and remained low until 6h. Flit mRNA increased to 
normal levels by 24 hours (Figure 26B). The TNFa response was similar in RAW cells 
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to BMDMs, levels were induced by 5 minutes, reaching maximum levels by 4h, and 
declining by 6h (Figure 26C). However, the regulation of Flil was different in RAW 
cells compared to BMDMs, down-regulation ofFlil was sustained in these cells past 24h 
(Figure 26D). 
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Figure 26: Flil is down-regulated within hours of LPS stimulation. Bone marrow 
derived macrophages (BMDMs) were isolated from mouse bone marrow and 
differentiated over six days. Cells were cultured in the presence of LPS (lf.Lg/mL) for 
various time-points (n=2). mRNA was extracted from cells and reverse transcribed for 
qPCR analysis ofiLl and 1NFa (A) or Flil (B). In a separate experiment (n=l), RAW 
cells were culture in (lf.lg/mL) LPS for the same time-points. rnRNA was extracted from 
cells and reverse transcribed for qPCR analysis of1NFa (C) or Flil (D). Analysis used 
the ~~Ct method and data was normalized to a control (media) sample for each 
experiment. A Student's unpaired two-tailed t-test compared control (media) to LPS 
stimulated macrophages. (n=l-2) 
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DISCUSSION 
Dysregulation of Flil has been shown to play a pathogenic role in fibrosis of the 
skin and heart 149' 205 ' 210. In the skin, down-regulation of Flil in endothelial cells and 
fibroblasts contributes to vasculopathy 155 and fibrosis 149 ' 154, respectively, in SSe. The 
purpose of our study was to determine whether Flil is down-regulated in the lung during 
experimental pulmonary fibrosis in mice. Under normal conditions, we determined that 
Flil is localized around blood vessels and within interstitial cells of the lung. Upon 
treatment with BLM, Flil transcript is down-regulated in the lung. We further 
determined that Flil is down-regulated in parenchymal cells and interstitial macrophages 
after lung injury. 
Because down-regulation of Flil has been previously described in fibrotic disease 
f h h d ki 149 154 205 · d t d · h h Flil · · 1 d · o t e eart an s n ' ' , we atme o etermme w et er IS mvo ve m 
pulmonary fibrosis, which is a common complication in SSe 6. Our studies have shown 
that Flil was down-regulated within the lung after BLM induced pulmonary fibrosis 
(Figure 22). Furthermore, Flil transcript was down-regulated in isolated parenchymal 
cells (Figure 23), which is suggestive of its regulation within fibroblasts. Down-
regulation may be a necessary event in fibrosis due to its important negative regulation of 
collagen transcription in fibroblasts . From in vitro studies, Flil was shown to have 
opposing roles to Etsl. Upon removal ofFlil from the collagen promoter during fibrosis, 
Etsl may activate transcription 150. The parenchymal population also contains other cell 
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types such as smooth muscle cells, pericytes, epithelial cells, etc. in which Fli1 may also 
be negatively regulated, and remains to be explored. 
In addition to Fli1 down-regulation in parenchymal cells (Figure 23), we have 
shown that Fli 1 is down-regulated in interstitial macrophages during pulmonary fibrosis 
(Figure 24). Regulation of Fli1 in macrophages has not previously been described in 
regards to fibrosis, and very little is known about Fli1 function in this cell type. Our 
results have confirmed previous reports that Fli1 is regulated at the transcriptional level 
by pro-inflammatory stimuli in macrophages 156. From our work, stimulation ofBMDMs 
or RAW cells with TLR agonists induced a rapid decrease in Flil transcript, which 
correlated with an increase ofpro-inflammatory cytokines (Figure 25 and 26). Fli1 was 
down-regulated within 2 hours in BMDMs and sooner within RAW cells . However, the 
induction of IL-l and TNFa. was induced within only 15 minutes for both cell lines . It 
still needs to be determined whether Flil is regulated directly by the TLR pathway, or 
whether it is regulated indirectly by paracrine signaling following the release of cytokines 
from macrophages. 
Similar to the role ofFlil in SSe, we had originally expected to see a decrease of 
Flil in endothelial cells from lungs ofBLM injected animals. Levels ofFlil were similar 
in endothelial cells from PBS and BLM injected lungs (Figure 23). Previous work from 
our lab has shown the role of Flil in endothelial cells through an endothelial cell specific 
knockout of Flil . This model recapitulated vasculopathy typically seen in SSe patients 
155
. Furthermore, Fli 1 was shown to control the expression of adhesion molecules such as 
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VE-Cadherin and CD31, which were unchanged within endothelial cells from the BLM 
model (Figure 18). This suggests that certain features of SSc-vasculopathy that are 
controlled by Fli1 may not be recapitulated in the BLM model of pulmonary fibrosis. 
In conclusion, we have shown that Fli 1 is down-regulated in multiple cell types 
during fibrosis. We have expanded upon previous studies that focused on the role of Fli 1 
in fibroblasts and endothelial cells in dermal fibrosis during SSe. Importantly, we have 
shown for the first time that Fli1 is down-regulated in the lung during fibrosis . Second, 
we have expanded the target cell types for Fli1 down-regulation during fibrosis to include 
macrophages and shown that it is regulated by pro-inflammatory stimuli in this cell type. 
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FUTURE DIRECTIONS 
Our studies have shown that Flil is rapidly down-regulated upon TLR stimulation 
m macrophages. The function of Flil in macrophages and its role during TLR 
stimulation still needs to be determined. Activation of TLRs induces multiple signaling 
pathways, including NFKB, MAPK pathways and activation of IRF transcription factors 
55
. It is worth noting, that other members of the Ets transcription factor family have been 
shown to bind Ets/IRF-cis regulatory elements, also known as EICE sequences with the 
. f IRF . . <:: 211 212 Am h E . . <:: h assistance o transcnphon 1actors ' . ong t e ts transcnphon 1actors t at 
have been shown to bind to these sequences are PU.l, Elfl and TEL. A possible future 
area of research would be to determine whether Flil is able to bind to these sequences or 
to cooperate with IRF transcription factors. It is also possible that Flil opposes the 
function of other Ets factors, similar to the control of CTGF and Collagen alpha2(1) in 
fibroblasts 150' 204, where Flil serves as a negative regulator and Etsl as an activator. 
Flil, a member of the Ets hematopoietic transcription factor family, has been best 
described for its function in megakaryopoesis 213 . From our studies in macrophages, Flil 
is rapidly down-regulated upon TLR stimulus, and is especially sensitive to LPS (Figures 
4.6 and 4.7), suggesting that Flil may also play a role in phagocytic cells during 
inflammation. Upon LPS stimulation, macrophages become activated and produce ROS, 
have increased capacity for phagocytosis, antigen presentation, and release of large 
amounts of cytokines 23 . Within mature phagocytic cells, Ets/IRF regulatory elements 
have been shown in genes that control the respiratory burst in macrophages 211 , pointing 
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to a role of other Ets factors in macrophage function. It needs to be determined whether 
the down-regulation of Fli1 after TLR stimulation is necessary for the pro-inflammatory 
functions of macrophages. 
Another aspect of Fli 1 function in macrophages is to determine whether Fli 1 
down-regulation in macrophages plays a role in fibrosis . An active area of research has 
recently focused on M1 /M2 macrophages skewing. Macrophages may become activated 
by classical mechanisms (M1) to kill microbes by phagocytosis, production of ROS and 
release of cytokines to activate other immune cells. It is now clear that M2 macrophages 
serve different functions that are associated with the development of fibrosis 54• 56 . 
Because Fli1 is known to function as a mediator of fibrosis in multiple cell types, it 
would be interesting to determine whether Fli1 is involved in M2 macrophage skewing. 
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CHAPTER 5: Flil regulates the expression of Tissue Inhibitor of Metalloproteinase 
3 in Cultured Dermal Fibroblasts 
PURPOSE 
Flit is a transcription factor expressed in hematopoietic and endothelial cells 144 . 
Our lab has shown that Flit is expressed at low levels in fibroblasts and plays a role in 
pathological fibrosis 149. Flit protein is negatively regulated by TGFp, a potent inducer 
of collagen production in fibroblasts that is implicated in fibrosis 151. Reduced expression 
of Flit was shown to play a role in SSe; dermal biopsies and dermal fibroblasts cultured 
from SSe patients both under-express Flit protein 149 . The study of Flit in tissue fibrosis 
has been limited due to the embryonic lethality of Flit-/- mice which have a hemorrhagic 
phenotype 153 . However, the association of Flit in fibrosis has been studied by the use of 
Flit heterozygote mice (or Fli 1 "knock -down") or in a partial deletion of Fli 1 where one 
of the protein interaction domains was removed (the C-Terminal Transactivation domain) 
154
. In vitro studies have revealed that Flit functions as an anti-fibrotic mediator, where it 
controls expression of extracellular matrix genes by binding to promoters and inhibiting 
transcription. These genes include collagen, CTGF and tenascin-C (TN-C) 150• 204• 214 . 
The purpose of this study was to identify further targets of Flil in fibroblasts and to 
determine the relationship of these targets to fibrosis in SSe. To determine this, 
expression of pro-fibrotic mediators was assessed in Flit +/- mice and TIMP3 was 
identified as a novel target. 
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AIM 4: Assess the regulation of TIMP3 in fibrosis and its regulation by Flil. As part 
of this aim, we wanted to determine A. whether Flil controls the expression ofTIMP3 by 
using a siRNA knockdown of Fli; and B. whether TIMP3 is dysregulated in SSe 
fibroblasts . 
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RESULTS 
Expression of pro-fibrotic mediators in lungs of Fli+l- mice 
The association of Fli 1 in fibrosis has been demonstrated by the fact that dermal 
biopsies from SSe patients show decreased expression of Flil protein 149. Furthermore, 
transcriptional repression of collagen was impaired in a mouse model where the C 
terminal transactivation domain (~CTA) was removed, resulting in increased collagen 
deposition in the skin 154. As part of our efforts to characterize the role of Flil in 
pulmonary fibrosis , lungs of Flil+/- mice were assessed for expression of pro-fibrotic 
mediators, with a focus on mediators that control collagen expression. We hypothesized 
that lungs of Flil+/- mice would over-express mediators previously shown to be 
regulated by Flil in vitro , and expanded the analysis to include previously unidentified 
molecules as an exploratory approach. As a confirmation that Flil mRNA is reduced in 
heterozygote mice, we used qPCR and determined that Flil mRNA is approximately 50% 
decreased in the lung compared to WT mice (Figure 27 A). We observed elevated 
expression of the interstitial collagen chains (Figure 27B) and other previously identified 
targets of Flil, which included CTGF/CCN2 and TN-C (Figure 27C). Interestingly, a 
novel target, TIMP3 was significantly increased, while the other members of the TIMP 
family were not elevated (Figure 270). Next, we wanted to determine whether TIMP3 is 
a target for Flil and explore its involvement in SSe fibrosis . 
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Figure 27. Expression of profibrotic genes in lung tissues from Flil+/- mice. 
Expression of genes that have been previously shown to be controlled by Fli 1 were 
examined in lungs ofWT v Flil+/- mice. mRNA expression analysis was done by qRT-
PCR of (A) Fli1 (B) Interstitial Collagens (C) Matrix Genes (D) TIMP family genes. 
Statistically significant differences were seen in Colla1 (p=0.043), Colla2 (p=0.045), 
TN-C (p=O.O 17), TIMP3 (p=0.03). Relative expression is quantified by the ~~Ct method 
and represented as fold change, normalized to tissue from lungs of a WT animal. 
Student's one-tailed, unpaired t-test compared WT to Flil +/- lung samples. (n=3-4, * p ~ 
0.05, **p ~ 0.01) 
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Regulation of TIMP3 expression by Flil in cultured dermal fibroblasts 
Flil has been shown to play a role in fibrosis through in vitro and in vivo 
techniques. Through in vitro studies, our lab has shown that Flil controls the production 
of collagen 149' 210 and other pro-fibrotic mediators such as CTGF and TN-C204' 214 . The 
role of Flil in mediating pathways that lead to degradation of collagen has not been 
explored. Collagen is degraded by enzymes known as matrix metalloproteinases 
(MMPs ), which are under further control by the tissue inhibitors of matrix 
metalloproteinases (TIMP) 215 . Because TIMP3 was elevated in our initial screen in 
lungs of Flil +/-mice (Figure 27), we hypothesized that Flil controls its expression. To 
determine this, Flil was knocked down using a viral delivery of siRNA to knock down 
the protein in human dermal fibroblasts. This approach reduced Flil mRNA by roughly 
75% (Figure 28A), while TIMP3 mRNA was significantly increased by 2 fold (Figure 
28B). Results were confirmed by immunoblotting, showing increased TIMP3 protein 
(Figure 28C). Next we aimed to determine whether TIMP3 is regulated by pro-fibrotic 
stimuli. 
Regulation ofTIMP 3 expression by TGF[J in cultured dermal fibroblasts 
TIMP3 has been shown to be regulated by TGF~ in chondrocytes, a cell type of 
parenchymal origin, similar to fibroblasts 216 . Flil is also regulated by TGF~, which 
induces phosphorylation and subsequent acetylation of the protein 151• 152 . We 
hypothesized that TIMP3 was also regulated by the pro-fibrotic cytokine TGF~ in 
fibroblasts. Cells were treated with TGF~ for 3h, 6h, 12h, 24h and 48h and compared to 
122 
A. B. 
Fli1 TIMP3 
** 
·-
c. 
TIMP3 
13-Actin 
scr siFiil 
Figure 28 TIMP3 is regulated by Flil. Normal fibroblasts cultured from dermal 
biopsies were grown to confluency in DMEM supplemented with 10% FBS. Cells were 
serum starved for 24h and infected with an adenovirus for siFli 1 or scrambled (scr) 
control virus for 48h. eDNA from scr and siFli 1 groups were analyzed for expression of 
human A. Fli 1 and B. TIMP3 mRNA expression. Data is representative of 5 experiments 
in 2 different primary cell lines. C. Increased expression of TIMP3 was confirmed by 
western blot (n=1). mRNA expression analysis used the ~~Ct method with GAPDH 
used as an internal control and data was normalized to siSCR. A two-tailed, unpaired 
Student's t-test compared expression of TIMP3 in siSCR v siFli I treatment groups (** p 
~ 0.01 , *** p ~ 0.001). 
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cells cultured in DMEM/1 0% PBS media as a control. TIMP3 levels in dermal 
fibroblasts were quantified by mRNA expression analysis (Figure 29A) and confirmed at 
the protein level by western blot (Figure 29B) after TGFP stimulation. mRNA and 
protein levels of TIMP3 showed similar results. TIMP3 was increased 3 hours after 
TGFP treatment and reached maximal induction at 24h. By 48h, TIMP3 protein and 
mRNA were decreased close to basal level. Next, we aimed to determine whether 
TIMP3 levels are increased during SSe. 
Up-regulation ofTIMP3 in cultured dermal fibroblasts from SSe patients 
Increased levels of TIMPl 217-221 and TIMP2 217' 222 ' 223 have been extensively 
reported in SSe serum or dermal fibroblasts. Elevated TIMP3 has only been reported at 
the mRNA level in dermal fibroblasts from SSe patients 224 . From our studies, we have 
shown that TIMP3 is regulated by TGFP (Figure 29) and Flil (Figure 28), both of which 
are dysregulated in SSe fibroblasts. This led us to hypothesize that TIMP3 protein would 
be elevated in SSe dermal fibroblasts . To determine this, TIMP3 was quantified at the 
protein and mRNA level in dermal fibroblasts from SSe patients that were age and gender 
matched with control dermal fibroblasts. Four pairs of SSe fibroblasts were compared 
(Nl and SScl, N2 and SSc2, N3 and SSc3/SSc4), where the third and fourth pair were 
matched to the same control. As expected, TIMP3 mRNA was significantly elevated 
when compared to dermal fibroblasts from controls (Figure 30A). For the first time, we 
have shown that TIMP3 is elevated at the protein level in SSe fibroblasts, in 3 out of 4 of 
the pairs tested (Figure 30B). 
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Figure 29: TIMP3 is regulated by TGFJ} in human dermal fibroblasts. Normal 
human dermal fibroblasts were grown to confluency in DMEM/10% FBS and serum 
starved for 24h. Cells were stimulated with 5ng/mL of TGF~ for 3, 6, 12, 24 and 48h. 
Cells were harvested an analyzed for A. mRNA and B. protein expression of TIMP3. 
mRNA expression analysis used the ~~Ct method with GAPDH used as an internal 
control and data was normalized to unstimulated cells. (n=l). 
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Nl SScl N2 SSc2 N3 SSc3 SSc4 
Figure 30: TIMP3 is overexpressed in human SSe dermal fibroblasts. Human dermal 
fibroblasts were grown in DMEM supplemented with 10% FBS. SSe fibroblasts are 
compared to a normal donor and matched for age, gender and race. A. TIMP3 mRNA is 
elevated in SSe dermal fibroblasts when compared to dermal fibroblasts from age and 
gender matched controls (n=12, p=0.02). B. TIMP3 protein is elevated in fibroblasts 
grown from SSe and matched donors (normal n=3, SSe n=4). mRNA analysis used the 
~~Ct method with GAPDH used as an internal control and data was normalized to 
control normal fibroblasts. A two-tailed, unpaired Student's t-test compared expression 
ofTIMP3 in SSe v Normal fibroblasts(* p ~ 0.05). 
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DISCUSSION 
The development of tissue fibrosis is believed to depend on a delicate balance of 
collagen deposition and collagen degradation. The degradation of collagen is a complex 
pathway that involves a family of matrix metalloproteinases (MMPs), which degrade 
extracellular matrix, and the tissue inhibitors of matrix metalloproteinases (TIMPs). 
There are only 4 TIMP family members that control the regulation of over 20 MMPs 215 . 
Each member of the TIMP family is able to recognize and inhibit the activity of multiple 
MMPs. Among this family, TIMP3 is unique in the ability to also inhibit proteins 
containing a disintegrin and metalloproteinase (ADAM) domains, including ADAM -17, 
also known as the TNFa converting enzyme 225 . This implicates TIMP3 in inflammation 
and fibrosis, two ofthe cardinal features of SSe 3. 
Here we have shown that Flil controls the expression of pro-fibrotic genes in the 
lung. Among the up-regulated genes in lungs from Fli 1 +/- mice were previously 
identified targets for Flil, including the interstitial collagens, CTGF and TN-C. We also 
identified and confirmed a new target ofFli-1 , TIMP3 . TIMP3 was further shown to be 
increased in dermal fibroblasts from SSe patients . 
The complexities of TIMP3 regulation by TGFP still remain to be answered. 
TIMP3 was up-regulated in response to TGFP after only 3h (Figure 29). TGFP also 
regulates the expression of Flil . It still remains to be answered whether Flil is solely 
responsible for the regulation of TIMP3, or whether TIMP3 is regulated by Flil 
dependent or independent mechanisms (Figure 31 ). 
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Figure 31: Working Model of TIMP3 Regulation. TIMP3 is regulated by both TGF~ 
and Fli I. It remains to be determined whether TIMP3 can be controlled directly by 
TGF~, via a Flit-independent mechanism or whether Flit down-regulation is required. 
TIMP3 is a pro-fibrotic mediator due to inhibitory action on MMPs, the primary enzymes 
that degrade collagen. 
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TIMP3 may be particularly important in the development of lung fibrosis. 
Importantly, TIMP3 null mice develop an emphysema like syndrome with enlarged 
alveolar spaces 226 and altered inflammatory response, possibly due to altered TNFa. 
activation 225 . In a mouse model of tissue fibrosis, space flight induced fibrotic changes 
around blood vessels that were associated witl1 up-regulation of TIMP3 227. In addition, 
lung biopsies from patients with IPF showed increased TIMP3 protein by IHC, which 
was localized in fibroblastic foci 215 . These data suggest that proper regulation of TIMP3 
by TGF~ and Fli 1 may be important in inhibiting fibrosis, particularly as it relates to the 
lung. 
Previous work in our lab has shown that Flil is responsible for the control of 
. 1 d . 11 h . 149 154 204 210 I hi d h Fli 1 . genes mvo ve m co agen synt es1s ' ' ' . n t s stu y we s ow 1 regu ation 
ofTIMP3, suggesting that Flil may also control the collagen degradation pathway. 
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FUTURE DIRECTIONS 
A major focus of our lab is to understand the biology behind Fli1 ' s role in tissue 
fibrosis . In an effort to better understand the regulatory mechanisms by which Fli 1 
controls fibrosis , future studies will take a large scale, genome-wide approach to 
determine gene targets of Fli1 in fibroblasts and in endothelial cells. Previous studies on 
endothelial cells from our lab have focused on the role of Flil in vasculopathy 155 , 
however, in this study (chapter 3) I have shown that endothelial cells also contribute to 
fibrosis and may regulate the response of fibroblasts to their environment. Furthermore, 
Fli1 has primarily been considered to exert negative regulation of genes by acting as a 
transcriptional repressor. Part of our goal in these studies will be to determine whether 
Fli1 may act as a transcriptional activator under certain situations. 
Previous studies from our lab have shown that Fli1 is down-regulated in SSe 
dermal biopsies and in SSe dermal fibroblasts 149 . Future studies on Fli1 in vivo will aim 
to determine whether down-regulation in fibroblasts is necessary or sufficient to induce 
tissue fibrosis . Evidence that Fli1 down-regulation is essential for development of 
fibrosis will prove Fli 1 as a target for therapeutic efforts 
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